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ABSTRACT OF DISSERTATION

BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA:
MOLECULAR FEATURES, EPIDEMIOLOGICAL RISK FACTORS, AND
EVIDENCE-BASED CLINICAL RECOMMENDATIONS
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an
emerging cancer of the immune system that can form around textured-surface breast
implants. In this dissertation, the cellular and molecular mechanisms of BIA-ALCL are
reviewed with a focus on the role of oncogenic JAK-STAT3 signaling in BIA-ALCL
tumorigenesis and progression. Herein, the epidemiology of BIA-ALCL is systematically
studied to better define the risk of BIA-ALCL and to determine the oncologic safety of
smooth surface devices relative to BIA-ALCL formation. Next, a systematic review is
conducted which critically appraises current clinical guidelines in order to establish an
evidence base to better inform diagnosis and treatment. Finally, a molecular investigation
is undertaken to determine the biological mechanisms of the disease which revealed
pervasive upregulation of the JAK-STAT3 pathway as a key pathogenic feature in BIAALCL tumorigenesis. Herein, a novel mechanism of tumorigenesis via the JAK-STAT3
pathway is proposed—highlighting its potential mechanistic role. Collectively, the
clinical research studies that comprise this dissertation demonstrate the oncologic safety
of smooth-devices while illustrating substantial knowledge gaps in the risk of BIA-ALCL
for commercially available textured breast devices in the U.S. market. This work also
provides evidence-based recommendations and updates on diagnosis and treatment.
Finally, this dissertation shows that BIA-ALCL tumorigenesis likely occurs through a
novel mechanism that facilitates malignant transformation from a chronic inflammatory
state through the JAK-STAT3 pathway.
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EPIGRAPH

It is not the critic who counts; not the man who points out how the strong man stumbles,
or where the doer of deeds could have done them better. The credit belongs to the man
who is actually in the arena, whose face is marred by dust and sweat and blood; who
strives valiantly; who errs, who comes short again and again, because there is no effort
without error and shortcoming; but who does actually strive to do the deeds; who knows
great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the
best knows in the end the triumph of high achievement, and who at the worst, if he fails,
at least fails while daring greatly, so that his place shall never be with those cold and
timid souls who neither know victory nor defeat.

Theodore Roosevelt
“The Man in the Arena” Excerpt from speech “Citizen in a Republic”
April 23rd, 1910
Later popularized by the U.S. Navy Seals
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CHAPTER 1. INTRODUCTION
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a novel Tcell lymphoma associated with textured-surface breast implants. Since the sentinel event,
which was first reported in the mid-to-late 90s, over 800 cases and 30 deaths have been
confirmed worldwide. Now provisionally classified as a unique clinical entity by the
World Health Organization, the disease has commanded significant attention from both
the scientific and clinical communities as well as regulatory agencies. In 2019, the U.S
Food and Drug Administration (FDA) conducted hearings on breast implant safety,
which included BIA-ALCL. Although the FDA concluded that textured-surface devices
did not meet the criteria to issue a ban, they later issued a class 1 recall, the strongest type
of recall, on all Allergan (Dublin, Ireland) textured breast devices which account for
greater than 90% of cases worldwide. Although relatively rare and despite the removal of
high-risk devices, the number of cases continues to rise as a result of increased physician
awareness and diagnostic advances, indicating the emerging nature of this disease.
The current risk of BIA-ALCL ranges between 1:355-1:200,000. However, when
considering risk profiles according to implant or patient specificity, manufacturer type,
and geographic status, there is significant variation. Further complicating the
interpretation of these data are the lack of well-defined study populations and
considerable variation in the reporting of epidemiologic parameters. Furthermore, with
the removal of Allergan devices, much of the available epidemiological data does little to
mitigate risk for patients and providers considering the use of a commercially available
textured device. Therefore, the current risk of BIA-ALCL is not well-defined and should
be examined further.
1

After two decades of investigation, the biological mechanisms responsible for
BIA-ALCL tumorigenesis and progression remain poorly understood. Early reports
suggested that a subclinical, peri-prosthetic biofilm infection may facilitate T-cell clonal
expansion. Lending credibility to this theory is the concept that capsular contracture, a
major complication associated with breast implants, arises from an infectious agent,
suggesting that capsular contracture and BIA-ALCL may share a common origin.
Nevertheless, more recent investigations have failed to establish a connection between
the breast microbiome and the malignant transformation of BIA-ALCL. Other studies
have used high-throughput genetic sequencing to focus on oncogenic changes in order to
better understand the pathogenesis of BIA-ALCL. Molecular studies have identified
activating mutations in TP53, DNMT3A, and the JAK-STAT3 pathway. While this
provides some insight into the pathophysiology of the disease, it remains unclear if these
oncogenic mutations lead to downstream events that facilitate malignant transformation.
As such, the molecular mechanisms responsible for BIA-ALCL tumorigenesis remain
largely unknown.
The majority of cases present as an acute-onset seroma greater than one-year
following implantation with a textured device. In order to establish a diagnosis, the
seroma should be drained and sent for cytopathology, which includes CD30
immunohistochemistry and flow cytometry to determine the presence of a clonal T-cell
gene rearrangement. National Comprehensive Cancer Network (NCCN) consensus
guidelines were established to guide the diagnosis and treatment of BIA-ALCL. Current
expert recommendations support complete surgical resection as the standard of care while
adjuvant therapy is reserved for advanced disease or cases refractory to surgical excision.

2

Despite the establishment of consensus guidelines and expert recommendations, the
evidence supporting those has not been systematically studied.
In summary, although the risk of BIA-ALCL has been previously determined,
limitations and differences in study design and reporting have failed to provide an
accurate risk estimate for currently available textured breast devices. Moreover, the lack
of knowledge regarding the molecular mechanisms and evidence guiding current
treatment recommendations is concerning. As such, further investigation into the
molecular features, epidemiological risk factors, and evidence supporting current clinical
recommendations is warranted.
The specific aims of this dissertation are as follows:
1) To determine if NCCN consensus guidelines and current treatment
recommendations are supported by evidence-based practices of BIA-ALCL
for complete surgical resection, adjuvant therapy, and breast reconstruction
following complete resolution.
2) To better define the current risk of BIA-ALCL in the U.S. breast implant
population
3) To determine the oncologic safety of smooth-surface breast implants with
respect to the malignant transformation of BIA-ALCL
4) To elucidate the molecular mechanisms of BIA-ALCL

Chapter two focuses on relevant clinical background information on BIA-ALCL,
while chapter three provides a narrative review on the cellular and molecular basis of the
disease while suggesting a novel mechanism of lymphomagenesis. The first specific aim
3

is addressed in chapter four. This chapter provides a comprehensive overview of BIAALCL and critically appraises current expert recommendations and guidelines in order to
better inform best evidence-based practices on diagnosis and treatment. The second and
third aims of this dissertation are examined in chapter five, which systematically reviews
the epidemiology of BIA-ALCL and assesses the oncology safety of smooth surface
devices. The fourth aim is addressed in chapter six. A molecular investigation using
hybridization-based transcriptional profiling was conducted in order to determine the
biological mechanisms responsible for BIA-ALCL. The final chapter of this dissertation
concludes by summarizing all pertinent findings in the context of the field while
establishing a research agenda for current and future investigations.
Collectively, the objectives and specific aims are to critically appraise the
evidence regarding the diagnosis and treatment of BIA-ALCL while simultaneously
assessing the oncologic safety of smooth surface devices, determining an accurate risk
profile for commercially available textured devices and elucidating the molecular drivers
of BIA-ALCL.

4

CHAPTER 2. BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL
LYMPHOMA: A CLINICAL UPDATE
Synopsis
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging
cancer of the immune system that is exclusively associated with textured-surface breast
implants. This clinical review provides an update on the diagnosis and management of
BIA-ALCL with an emphasis on major advances. The epidemiology and
pathophysiology of the disease are also reviewed, focusing on current paradigm shifts
and highlighting current controversies related to disease classification. Finally, we
conclude by discussing medicolegal and ethical issues surrounding BIA-ALCL while
establishing a future basic science and clinical research agenda that is central to
improving patient safety.

5

Background
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a nonHodgkin lymphoma subtype that arises around textured-surface breast implants.1 Since
first being described in the mid-to-late ‘90s, over 800 cases have been pathologically
confirmed worldwide.2 Cases of BIA-ALCL vary widely by both geography and textured
device characteristics, suggesting a complex individual risk profile.3,4 Allergan (Dublin,
Ireland) Biocell textured implants, which are responsible for over 90% of reported cases
worldwide when the device history was known, are now subject to a worldwide recall.
Despite the removal of these high-risk devices from the global market, other textured
devices remain commercially available. Given the emerging nature of the disease and the
millions of patients still at risk for developing the disease, heightened awareness and a
thorough knowledge of BIA-ALCL is required.
Over the past several years, plastic surgeons, together with oncologists and
pathologists, have standardized the current guidelines on diagnosis and treatment—as
failure to appropriately identify or manage BIA-ALCL cases can lead to patient demise.
This evidence-based narrative review aims to provide clinical updates on the
epidemiology and pathophysiology of BIA-ALCL while placing a particular emphasis on
major advances in diagnosis and treatment. Herein, we highlight evidence-based surgical
and therapeutic strategies for achieving complete remission. Finally, we discuss
regulatory oversight issues surrounding textured devices and breast implants in general
and conclude with establishing future research priorities.
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Epidemiology
Since first being described, the epidemiological knowledge of BIA-ALCL has
evolved considerably.3–5 Current data suggest that the risk of developing the disease is
higher than previously thought. Recently, Cordeiro et al. estimated a 26-year cumulative
incidence of 1:355 patients with an Allergan Biocell implant and a patient-specific
incidence rate of 0.311 cases per 1,000 person-years (95% CI: 0.018-0503).4 They also
demonstrated an implant-specific risk of BIA-ALCL at 1:602 devices. However, with the
FDA removing Allergan devices from the market, it is unclear what the risk of BIAALCL is for commercially available textured devices. Data from Doren et al. 3 provide a
risk estimate of Mentor (Mentor Worldwide LLC, Irvine, Calif.) Siltex implants at 1:51 4
28. Calobrace et al. estimate a global combined risk of BIA-ALCL for Sientra (Santa
Barbara, Calif.) and Silimed (Rio de Janeiro, Brazil.) implants at 1:200 000.6 Magnusson
and colleagues challenged this calculation and found Silimed implants to have the highest
risk of BIA-ALCL at 1:2832 compared to Allergan Biocell 1:3345 and Mentor Siltex at
1:86 029.7 From both a methodologic and epidemiologic standpoint, the Calobrace study
was not designed to determine the risk of BIA-ALCL. Many epidemiological studies of
BIA-ALCL, including the Doren study, have been limited by inadequate post-market
surveillance. Without the knowledge of global sales data standardized across different
populations (which may carry different nonequivalent, unmodifiable risks), actual
comparisons cannot be evaluated.
Importantly, the only currently modifiable risk factor identified to date remains
surface texturization of the implanted device. Although previously confined to the breast
implant pocket, gluteal implant-associated anaplastic large cell lymphoma associated
7

with textured devices have now been reported, providing strong evidence that anatomic
location does not play a significant role in tumor development.8 Moreover, recently
described cases in the transgender breast implant population indicate that the disease does
not show a predilection for gender.9 The U.S. FDA currently acknowledges a risk of
developing ALCL from a textured device at 1:3817-1:30 000.10 However, heterogeneity
in the worldwide literature, along with differences in regulatory agency estimates,
underscores the significant geographic variation in the reported risk. Although the risk of
BIA-ALCL remains relatively low, the increasing number of global cases emphasizes the
emerging nature of the disease.

Pathogenesis
This section provides a cursory overview of the pathogenesis of BIA-ALCL
relevant to practicing clinicians. An in-depth analysis of the cellular and molecular
mechanisms is outside of the scope of this article and has been reviewed in detail
elsewhere.11
2.1.1

Bacterial wall lipopolysaccharide hypothesis
Early investigations into the pathogenesis of BIA-ALCL suggested that

subclinical, periprosthetic biofilms drive BIA-ALCL tumorigenesis.12 This attractive
hypothesis has medical precedent, as a causal link between some gastric-associated
cancers and bacterial invasion (Helicobacter pylori) is well-established.13 LochWilkinson et al. demonstrated that the risk of BIA-ALCL increases as the surface area
increases, a major predictor of bacterial load on implants, with the highest risk of BIAALCL residing in implants with the most aggressive surface characteristics.5 These
8

researchers implicated the gram-negative bacillus Ralstonia pickettii in altering the
implant pocket microbiome and causing oncogenic transformation of BIA-ALCL.12
However, Ralstonia is a commonly identified pathogen in water sources, and the initial
studies linking Ralstonia have not been replicated, suggesting this once-promising
hypothesis may be inaccurate. In a subsequent study using 16S RNA sequencing, Walker
et al. demonstrated that the microbiome has no apparent role in BIA-ALCL formation.14
To that end, the microbiome in the non-diseased breast has yet to be established and is
currently the focus of federally-funded research. The biofilm hypothesis has since been
adapted into a lipopolysaccharide-driven carcinogenesis, which has been shown in oral
squamous cell carcinoma and colon cancers.15 However, a mechanism by which LPS
facilitates malignant transformation in even well-described cancers remains incompletely
understood. In a prospective study of BIA-ALCL at the senior author’s institution, 24
patients included intraoperative technique details at time of original breast implant
placement. BIA-ALCL patients had received betadine irrigation (12 patients: six 50%
Strength, four 25% Strength, two “tea-colored”) and seven patients had received
antibiotic irrigation: (five Bacitracin/Cefazolin/Gentamicin and two
Polymyxin/Bacitracin) and still went on to develop disease (Figure 1). To date, no
operative strategy has been shown to decrease the future risk of BIA-ALCL. Worldwide
clusters of disease represent heightened disease awareness and excellent long-term
surveillance, and misattributing clusters to “poor breast implant technique” without any
supportive data, only shames surgeons and discourages the reporting of cases.
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2.1.2

Cancer genetics
Recent molecular investigations have provided novel insights into the biological

mechanisms responsible for BIA-ALCL lymphomagenesis, but much work remains.
Over the last five years, high throughput genetic sequencing technologies have enabled
the identification of somatic mutations in DNMT3A and the JAK-STAT3 pathway, as
well as germline mutations in TP53.16 Data from Di Napoli and colleagues17 has
identified the JAK-STAT3 pathway as a key component of disease progression.
Unpublished studies from our laboratory mechanistically corroborate these data and
suggest JAK-STAT3 as a potential actionable therapeutic target with candidate drugs
(e.g., JAK inhibitors), which may prove to be beneficial in patients with advanced or
surgically unresectable disease. The prevailing hypothesis behind aberrant JAK-STAT3
pathway activation considers an overactivated immune system driving the malignant
transformation of capsular lymphocytes. Interestingly, the JAK-STAT3 pathway
mechanistically links chronic inflammation and other cancers, including lymphomas.18
Comprehensive in vitro and ex vivo studies utilizing BIA-ALCL tissues are required to
identify the inciting event responsible for driving JAK-STAT activation and is the current
focus of our research group.
2.1.3

The role of chronic inflammation and implant surface characteristics
The link between chronic inflammation and cancer has been well established. 13

Our group has provided evidence that a chronically overactivated immune system
predisposes to errors in DNA replication and subsequent driver gene mutations (e.g.,
STAT3).19,20 Alternatively, some have postulated that chronic trauma to the breast pocket
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induces a chronic inflammatory state that cultivates a microenvironment that favors
tumorigenesis.21 However, a low incidence of BIA-ALCL despite millions of patients
with textured implants indicates a host-specific immune susceptibility for developing the
disease. The foreign body reaction has been an attractive area of research in establishing
a chronic inflammatory state, suggesting investigation in host-implant interactions may
elucidate pathogenic signaling. Work by Turner and colleagues has investigated the role
of aryl hydrocarbons, a conserved chemical structure found on the textured implant
surfaces, to drive cellular proliferation of capsular lymphocytes through their associated
receptor.22 An alternative hypothesis by Kadin et al. suggests an allergen-driven etiology
from a chronic allergic response to the implant itself. However, a unifying hypothesis
linking immune responses and carcinogenesis remains elusive23, and underscores the
critical need for comprehensive genetic studies to identify patient-specific risk profiles.
2.1.4

BIA-ALCL: lymphoproliferative disorder vs. lymphoid neoplasm
The debate over the classification of BIA-ALCL as a “benign condition”, as

opposed to a lymphoid malignancy has served to limit the initiation of surveillance and
definitive treatment. Some authors have argued that BIA-ALCL is a lymphoproliferative
disorder that encompasses a broad spectrum of CD30+ benign seromas, malignant
seromas, and distant metastasis.24 Recently, experts from the World Health Organization
(WHO) have provisionally classified BIA-ALCL as a unique lymphoid neoplasm, and
specifically not a lymphoproliferative disorder.25 Advanced disease is the end of the
spectrum of cancer stages and substantiates the WHO classification of BIA-ALCL as a
lymphoma rather than benign or lymphoproliferative. Untreated BIA-ALCL leads to
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invasive, metastatic disease—and misclassification or overt failure to diagnose this
disorder can lead to patient death.26

Diagnosis and Treatment
2.1.5

Clinical presentation
BIA-ALCL typically presents as an acute-onset periprosthetic fluid collection

greater than one year following implantation in approximately 80% of cases. Patients
may also present with lymphadenopathy (4-12%) or a palpable mass (8-24%). Less often
(<5%), patients may present with capsular contracture or cutaneous involvement. The
median time to presentation is 7-10 years (range, 1-28 years). BIA-ALCL is equally
distributed between cosmetic and reconstructive patients, suggesting that history of a
previous malignancy such as breast cancer does not predispose to the subsequent
development of the disease. Previously confined to the breast implant pocket, reports of
gluteal implant-associated anaplastic large cell lymphoma associated with textured breast
devices have now surfaced, giving the impression that anatomic location may not play a
significant role in tumor development.8 Moreover, recently described cases in the
transgender breast implant population indicate that the disease does not show a
predilection for gender.9
2.1.6

Diagnostic workup
The presentation of any delayed seroma should raise immediate clinical suspicion

for BIA-ALCL (Figure 2-1). It is important to note that all implants contain a trace
amount (5-10 mL) of fluid in the periprosthetic space, which is normal and does not
12

warrant further screening. Obtaining a detailed clinical history and performing a thorough
physical exam is paramount. After ruling out other causes of late seromas (e.g.,
infection), a diagnostic workup should commence with fine-needle aspiration (>50mL) of
the seroma under ultrasound guidance or in consultation with interventional radiology.
The aspirate should be sent for cytopathology with the request to rule-out BIA-ALCL. The
order set should include CD30 immunohistochemistry and flow cytometry to determine
the presence of a clonal T-cell gene rearrangement. In order to establish a diagnosis of
BIA-ALCL, three criteria must be met: Monoclonal expansion of and strong expression
of CD30+ T-cells, and the presence of large, anaplastic lymphoma cells. Importantly,
CD30 positivity alone is not a pathognomonic feature and does not constitute a diagnosis
of BIA-ALCL, as benign seromas have been found to harbor CD30+ lymphocytes. The
other pathogenic features must also be present for a definitive diagnosis. Specific
protocols for pathologic diagnosis have been established.27,28 In order to identify 95% of
randomly distributed lesions in specimens without grossly identifiable lesions, 12
capsular biopsies should be taken, two from each side of the face of a cube.28
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Figure 2-1. Patient Example and Surgical Treatment
This woman presented 7 years after bilateral cosmetic breast augmentation with swelling
of the left breast and palpable lymphadenopathy (A). She underwent an incisional biopsy
of the capsule, drainage of the effusion, and subsequent complete surgical excision that
included implant removal and total capsulectomy with lymph node excisional biopsy by
ultrasound guidance (B and C). Effusion demonstrated large cells (D: Wright
Giemsa,31000; E: Anti CD30 immunocytochemistry,31000) capsule and excised lymph
nodes were negative for lymphoma. The diagnosis rendered was breast implant–
associated anaplastic large-cell lymphoma, Ann Arbor stage IE, MD Anderson Cancer
Center stage 1A. Scanning electron microscopy demonstrates the textured surface of the
involved breast implant with attached cells. (F; magnification, 31,000) The patient did
not receive radiation or chemotherapy and underwent surveillance by positron emission
tomography–computed tomography scan every 3 months the first year and every 6
months after the first year. Patient is disease free after 2 years of follow-up. Reprinted
with permission. © (2016) American Society of Clinical Oncology. All rights
reserved. Clemens et al: Complete Surgical Excision Is Essential for the Management of
Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma J Clin Oncol
Vol. 34 (2), Year: 2016 160-168.
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Hanson et al. recently developed a novel, low-cost screening test which can be
deployed in the clinical setting.29 Using a commercially available (R&D Systems,
Minneapolis, MN), CD30-specific enzyme-linked immunosorbent assay (ELISA), they
standardized and validated the ability of the assay to reliable detect BIA-ALCL in seroma
fluid. The authors demonstrated that the assay could effectively be used to evaluate
suspicious seromas, presenting a reliable and more rapid alternative to standard CD30
immunohistochemistry. Nevertheless, it is important to reinforce that this should only be
employed as an office-based screening tool. Definitive diagnosis still requires further
pathologic evaluation.
2.1.7

Oncologic resection and adjuvant therapy
One of the most significant advances highlighted in this update has come from

seminal work by Clemens et al. on the surgical treatment of the disease.30,31 When
diagnosed and treated in accordance with NCCN guidelines, BIA-ALCL carries an
excellent prognosis, with five-year overall and event-free survival rates approaching 91%
and 46%, respectively.32 With complete surgical excision, event rates are reduced to 0%
(Stages T1, T2) and 14.3% for Stage T3. A TNM staging system has since been proposed
and validated, which replaces the previously used Ann Arbor Lugano Classification for
BIA-ALCL. The MD Anderson TNM staging system of BIA-ALCL is summarized in
Table 2-1 and an illustration is provided in Figure 2-2. Collectively, these data
demonstrate the clinical superiority of complete surgical resection over adjuvant therapy.
This is reflected in NCCN guidelines, which highlight en bloc resection as the standard of
care while adjuvant therapy is reserved for MD Anderson Stages IIB-IV.
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Table 2-1. MD Anderson Staging System for BIA-ALCL
TNM Classification
Primary tumor (T)
T1
T2
T3
T4
Regional lymph
nodes (N)
N0
N1
N2
Distant metastasis
(M)
M0
M1
Stage
1A
1B
1C
IIA
IIB
III
IV

Description
Confined to effusion or a layer on luminal side of capsule
Early capsule infiltration
Cell aggregates or sheets infiltrating the capsule
Lymphoma infiltrates beyond the capsule

No lymph node involvement
One regional lymph node (+)
Multiple regional lymph nodes (+)

No distant spread
Spread to other organs/sites
T1N0M0
T2N0M0
T3N0M0
T4N0M0
T1-3N1M0
T4N1M0
T (any) N (any) M1
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Figure 2-2. This TNM system was modeled after the American Joint Committee on
Cancer TNM staging system for solid tumors.
Reprinted with permission. © (2016) American Society of Clinical Oncology. All rights
reserved. Clemens et al: Complete Surgical Excision Is Essential for the Management of
Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma J Clin Oncol
Vol. 34 (2), Year: 2016 160-168.
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The preoperative workup should include several laboratory tests, which are
summarized in Table 2-2. PET-CT may be used to assess for the presence of capsular
masses or chest wall extension and may be helpful in guiding the surgical approach. It is
highly recommended that oncologic resection should be done by, or in collaboration with
a surgical oncologist in order to minimize the risk of locoregional recurrence. En bloc
resection should proceed in the standard oncologic fashion, which includes placement of
orientation sutures, deployment of surgical clips within the tumor bed, and utilizing
sterilized instruments if performing a contralateral explantation.33 Because BIA-ALCL
does not involve the breast parenchyma, mastectomy is not indicated.

18

Table 2-2. Recommended Preoperative Laboratory Testing
Preoperative test
Notes
CBC w/ diff
CMP
LDH and Hep B

Order LDH and Hep B if chemotherapy is
being considered

Bone marrow
biopsy

Consider if high suspicion of advanced disease
(locally aggressive or lymph node metastasis)

PET-CT

Used to assess for chest wall involvement and
to guide surgical resection

CBC w/ diff Complete Blood Count with Differential; CMP,
Complete Metabolic Panel; LDH, Lactate Dehydrogenase; Hep B,
Hepatitis B; PET-CT, Positron Emission Tomography-Computed
Tomography.
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For asymptomatic patients, the FDA, ASPS, and the authors do no suggest
prophylactic implant removal at this time. Complete capsulectomy encompasses the
removal of the entire capsule. Conversely, en bloc resection is an oncologic procedure
with the goal of achieving clear margins. This marks a clear distinction between complete
capsulectomy and en bloc resection. Therefore, in a patient without clinically proven
disease, complete capsulectomy alone is insufficient as a risk-reducing operation.
2.1.8

Oncologic surveillance
Per NCCN guidelines, patients should be followed closely by an oncologist every

3-6 months for two consecutive years in order to monitor for disease recurrence. PET-CT
is the preferred imaging modality used to monitor for locoregional recurrence or distant
metastasis.
2.1.9

Breast reconstruction after treatment for BIA-ALCL
Given the relatively low recurrence rate of 4% at five years,34 breast

reconstruction can be offered after definitive oncologic treatment for BIA-ALCL. The
senior author has proposed a treatment algorithm based upon the MD Anderson TMN
staging classification whereby patients with surgically resectable disease (stage IA-IC)
are offered either immediate reconstruction or delayed reconstruction following
surveillance PET-CT at 3-6 months. Patients with advanced disease (stage IIA-IV) are
offered delayed reconstruction following surveillance imaging at 6-12 months after any
adjuvant therapy. The approach to breast reconstruction may include implant
replacement, which should proceed using a smooth device, as discussed below. The
possibility of device-induced recurrence may deter patients from implant-based
20

reconstruction, and alternative methods include mastopexy, autologous tissue transfer, or
serial fat grafting. Patient satisfaction has been shown to be excellent after reconstruction
following BIA-ALCL treatment.

Medicolegal and Ethical Considerations
2.1.10 Breast Implant Safety and Regulatory Oversight
Significant concerns over the safety of breast implants have reemerged at the
forefront of plastic and reconstructive surgery. Recently, a controversial paper
resurrected the age-old theory that silicone breast implants may be associated with an
increased risk of rare harms.35 Collectively, these concerns prompted the FDA to conduct
public advisory hearings on breast implant safety in March 2019. The evidence presented
resulted in newly proposed black box warnings for all breast implants (Table 2-3). While
it is important to note that these warnings have yet to be finalized, plastic surgeons should
expect to see some iteration of these warnings on package inserts for all breast devices in
the very near future.
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Table 2-3. Proposed U.S. Food and Drug Administration Breast Implant Label
Warnings
Description
Breast implants are not considered lifetime devices. The longer people have them, the
greater the chances are that they will develop complications, some of which will
require more surgery
Breast implants have been associated with the development of a cancer of the immune
system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
This cancer occurs more commonly in patients with textured breast implants than
smooth implants, although rates are not well defined. Some patients have died from
BIA-ALCL
Patients receiving breast implants have reported a variety of systemic symptoms such
as joint paint, muscle aches, confusion, chronic fatigue, autoimmune diseases and
others. Individual patient risk for developing these symptoms has not been well
established. Some patients report complete resolution of symptoms when the implants
are removed without replacement
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2.1.11 Implant Screening and Patient Education
The most recent FDA guidance also specifically addresses screening for implant
rupture. The draft calls for updated screening, which would supersede the prior
recommendation for MRI evaluation at two years post-implantation and every three years
thereafter. However, screening is not widely adopted as it is not covered by many
insurance policies. This is just one of many considerations that should be discussed with
patients during the informed consent process. All patients receiving an implant should be
made aware of the existence of BIA-ALCL, current incidence, common presenting
symptoms, and general screening recommendations. The informed consent process is
paramount to the preservation of patient autonomy and raises the question of how best to
retrospectively inform patients whose implants were placed prior to current knowledge of
BIA-ALCL.

Disease Reporting
All suspected or confirmed cases of BIA-ALCL should be reported to the Patient
Registry and Outcomes For breast Implants and anaplastic large cell Lymphoma (ALCL)
etiology and Epidemiology (PROFILE) registry
(https://www.thepsf.org/research/registries/profile). PROFILE is a collaboration between
the Plastic Surgery Foundation, the American Society of Plastic Surgeons, and the FDA.
PROFILE currently acknowledges 871 cases of BIA-ALCL and two cases occurring
solely with exposure of a textured-surface tissue expander followed by smooth-only
implants. Surgeons should consider the risks and benefits of tissue expander breast
reconstruction with a textured vs. smooth expander. For this reason, we strongly suggest
23

that expansion of the breast pocket should proceed using a smooth surface expander.
Echoing this concept, recent data have demonstrated both the safety and efficacy of
smooth expander reconstruction.36

Insurance Coverage and Diagnostic Codes
Insurance coverage of BIA-ALCL has expanded in recent years. ASPS has
provided further guidance on insurance coverage for third-party payers at the following
link: https://www.plasticsurgery.org/documents/HealthPolicy/Reimbursement/Insurance-2017-BIA-ALCL.pdf. A detailed list of relevant
diagnostic and procedural codes is summarized in Table 2-4.
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Table 2-4. Diagnostic and Procedural Codes for BIA-ALCL
Code

Description

Numeric
definition

ICD
Anaplastic large cell lymphoma kinasenegative, extranodal, solid organ sites
Unspecified lump in breast, nodule, mass, or
swelling of the breast

C84.79

N63

Enlarged lymph node
Other specified disorders of the breast

R59.9
N64.4

Fine needle aspiration with imaging guidance
Breast biopsy, open, incisional
Excision of chest wall tumor
Removal intact mammary implant
Breast periprosthetic capsulectomy
Biopsy/excision, lymph node; open or deep
axilla

10022
19101
19260
19328
19371
38525

CPT

Source: American Society of Plastic Surgeons. ICD, International
Classification of Diagnostic Codes-10th Revision; CPT, Current
Procedural Terminology Codes.
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Defining Research Priorities
Stakeholders, including The Plastic Surgery Foundation and the Aesthetic Surgery
Education and Research Foundation, have recently prioritized the funding of projects
related to breast implant safety. Due to its uncommon incidence, investigation into the
pathogenesis of BIA-ALCL has been limited to in vitro and ex vivo models. Future basic
science research initiatives should focus on the development of an animal model of BIAALCL to answer questions about implant texturization, chronic inflammation driving
carcinogenesis, and to clarify immune susceptibility profiles. These studies not only
expose the complex etiology of the disease but also suggest areas for novel treatment in
metastatic disease.
In addition to basic science investigation, several clinically relevant questions
remain. Understanding population-based risk profiles will allow plastic surgeons to better
inform patients with textured devices about their specific risk. Only then can a complete
discussion about prophylactic implant removal occur. Attempts to streamline diagnosis,
through point-of-care testing in the office,29 would improve time to treatment and should
be actively explored. While effective treatment strategies exist, plastic surgeons have the
opportunity to use BIA-ALCL as a model to uncover scientific truths broadly applicable
to all ALK- ALCLs. Thus, research efforts focused on BIA-ALCL have the potential to
impact a larger subset of lymphoma patients, not just breast-implant associated
lymphomas.
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Conclusions
Major advances in the diagnosis and treatment of BIA-ALCL in recent years have
led to significant improvements in overall and disease-free survival. Most notably, en
bloc resection alone is capable of achieving complete remission for the majority of cases
and is now the standard of care. Despite the removal of the high-risk devices from the
U.S. and other markets around the world, the number of cases will continue to rise for the
foreseeable future. Given that a significant number of patients worldwide still live with
these devices, research to understand the etiology of the disease and clarify individual
risk profiles must continue. Only through these efforts can plastic surgeons have
informed discussions with their patients about BIA-ALCL.
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CHAPTER 3. CELLULAR AND MOLECULAR MECHANISMS OF BREAST
IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA
Abstract
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an
emerging and highly treatable cancer of the immune system that can form around
textured-surface breast implants. While the underlying etiology has yet to be elucidated,
an emerging theme—linking pathogenesis to a chronic inflammatory state–-continues to
dominate the current literature. Specifically, the combination of increasing mutation
burden and chronic inflammation leads to aberrant T-cell clonal expansion—however the
impetus remains largely unknown. Proposed mechanisms include a lipopolysaccharide
endotoxin response, oncogenic transformation related to viral infection, associated
trauma to the breast pocket, particulate matter digestion by capsular macrophages,
chronic allergic inflammation, and genetic susceptibility. The JAK/STAT3 pathway is a
major signaling pathway that regulates a variety of intracellular growth and survival
processes. Constitutive activation of JAK/STAT3 has been implicated in several
malignancies including lymphomas and has recently been identified as a potential key
mediator in BIA-ALCL. The purpose of this article is to review the cellular and
molecular mechanisms of BIA-ALCL with a focus on the role of oncogenic JAK/STAT3
signaling in BIA-ALCL tumorigenesis and progression. Selected experimental work from
our group on aberrant JAK/STAT3 signaling in BIA-ALCL is also included. We will
discuss how an inflammatory microenvironment may facilitate malignant transformation
through the JAK/STAT3 pathway—highlighting its potential mechanistic role. Our hope
is that further investigation of this signaling pathway will reveal avenues for utilizing
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JAK/STAT3 signaling as a prognostic indicator and novel therapeutic target in the case
of advanced disease.

Background
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an
emerging, CD30+, anaplastic lymphoma kinase (ALK)-negative, non-Hodgkin’s
lymphoma associated with textured-surface breast implants.1,37–41 Since first being
described in the mid to late ‘90s, over 800 cases have been reported worldwide.2,42,43 The
current average lifetime risk is estimated between 1:355 – 1:30,000 persons with a
textured surface breast implant which further varies according to manufacturer specific
risks.3,44 The disease remains equally distributed among cosmetic and reconstructive
patients,3,45 suggesting that a history of previous malignancy (e.g., breast cancer) is not an
independent risk factor for the development of BIA-ALCL.
After nearly two decades of research, the molecular mechanisms responsible for
aberrant T-cell clonal expansion in BIA-ALCL remain poorly understood.46 General
consensus implicates the induction of a chronic inflammatory state in in a genetically
susceptible host that leads to subsequent malignant transformation. The exact cause of the
chronic inflammation, whether it is a response to a lipopolysaccharide (LPS) endotoxin,12
trauma to the breast pocket,21 viral infection,17 allergen-driven,23 or particulate matter
digestion from the textured-implant surface remains highly debated and is the focus of
our research group and several others around the world.47–50 Interestingly, recent
molecular studies have identified novel, activating mutations in the Janus kinase (JAK),
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and signal transducer and activator of transcription factor three (STAT3) pathway as a
major risk factor for the development of BIA-ALCL.16,20,51–54
The JAK/STAT signaling pathway is a major intracellular signaling pathway that
regulates a variety of biochemical processes.55 In humans, there are four members of the
JAK family of kinases: JAK 1–3 and Tyrosine Kinase 2. The STAT protein family is
comprised of seven members: STAT 1–4, 5a, 5b, and 6. External cues, cytokines, growth
factors, and interleukins, bind to JAK receptors located in the cytoplasm and activate
STAT via phosphorylation (Figure 3-1). Phosphorylated STAT receptors dimerize and
translocate into the nucleus to regulate genes that are crucial for cancer inflammation in
the tumor microenvironment. Interestingly, aberrant STAT3 signaling has been
established as a mechanistic link between chronic inflammation in non-BIA-ALCL
cancers, including B and T cell lymphomas, and among the latter systemic anaplastic
large cell lymphomas.18,56–60 Persistent STAT3 activation has been definitively linked to
improved tumor survival and cell proliferation, increased angiogenesis and tumor
metastasis. A clearer understanding of the direct link between JAK/STAT signaling and
BIA-ALCL is required. This study aims to critically review the cellular and molecular
mechanisms of BIA-ALCL with a focus on the current evidence supporting the critical
role that JAK/STAT3 plays in the malignant transformation of BIA-ALCL and offers
several novel hypotheses for future investigation.
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Figure 3-1. Overview of JAK/STAT3 signaling pathway
The binding of an extracellular ligand (e.g. IL-6) to its receptor (e.g. IL-6R), activates
JAK via intrinsic tyrosine kinase activity. Activated JAK receptors transfer a phosphate
group to the SH2 domain of cytoplasmic STAT3 proteins resulting in STAT3 activation.
Phosphorylated STAT3 forms a homodimer that translocates into the nucleus to regulate
genes that are critical for tumor promoting inflammation, as well as tumor cell growth
and survival, migration and invasion, and angiogenesis. Constitutively activated JAKSTAT3 pathway facilitates genetic instability (e.g. activating STAT3 mutations) and
promotes tumorigenesis through a feed forward loop. Suppressor of cytokine signaling
three (SOCS3) is an important inhibitor of JAK.
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Foreign Body Response to Implantable Devices
Breast augmentation or reconstruction with an implantable device, including tissue
expanders or breast implants initiates a complex immunobiologic cascade known as a
“foreign body reaction.”61 Briefly, the human body utilizes a coordinated local and
systemic immune response to the biologic components of the implant in an attempt to
phagocytize and eliminate detected foreign antigens. In instances where phagocytosis of
the offending agent is unsuccessful, macrophages and giant cells accumulate and lay
down collagen networks to develop a fibrous capsule around the source (Figure 3-2).
Following biomaterial implantation, host reactions include injury, blood-material
interactions, provisional matrix formation, acute inflammation, chronic inflammation,
granulation tissue development, foreign body reaction, and fibrous capsule
development.61 Initially, local inflammatory signaling drives non-specific protein
adsorption, fibrin-predominate provisional matrix formation and trafficking of immune
cells to the site of injury.62 Neutrophil infiltration and mast cell degranulation causes a
local increase in the concentration of interleukin-4 (IL-4) and interleukin-13 (IL-13),
cytokines typically associated with a Th2 or allergy-mediated immune response.
Recently, Kadin et al identified IL-13 in BIA-ALCL specimens which led them to
speculate that BIA-ALCL may occur in response to an allergen, from either the breast
implant surface or an LPS endotoxin.63,64
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Figure 3-2. Foreign body response to implantable devices
Immediately after implantation, fibrin deposition and non-specific protein adsorption
leads to provisional matrix formation at the tissue-implant interface. Following
provisional matrix formation, monocytes and neutrophils infiltrate the implant space,
characterizing the acute inflammatory process. Monocytes differentiate into
proinflammatory M1-macrophages. Simultaneously, mast cell degranulation with
histamine release regulates the acute inflammatory response to implantable devices.
Interluekin-4 (IL-4) and interleukin-13 (IL-13) also released by mast cells modulates the
magnitude of the foreign body response. Following acute inflammation, macrophages and
lymphocytes invade the biomaterial interface, marking the beginning of the chronic
inflammatory response. IL-4 and IL-13 released from mast cells and Th2 lymphocytes
(not shown) activates M2 macrophages that regulate wound healing through generation
of a collagen-based extracellular matrix (ECM) in conjunction with fibroblasts.
Coalescence of M2-macrophages leads to the formation of foreign body giant cells. Over
time, the ECM matures to form the fibrous capsule with a low abundance of immune
cells and fibroblasts.
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Following recruitment of monocytes/macrophages and other mononuclear cells to
the implant site, persistent frustrated phagocytosis65 ultimately leads to coalescence of
macrophages into multinucleated giant cells, infiltration of fibroblasts and extracellular
matrix protein deposition, followed by formation of the peri-implant fibrous capsule.61
Nuclear Factor κB (NF-κB), transforming growth factor β (TGF-β) and matrix
metalloproteinase (MMP) signaling pathways figure prominently in this transition. At
this point, the characteristics of the chronic immune reaction change—the implant is
essentially walled off from the rest of the body in a protected, immune-privileged, and
relatively hypoxic environment—but the chronic immune response to the implant
remains. As long as the immune cascade remains activated, the risk of DNA alteration in
overstimulated cells increases and chronic stimulation could lead to the activating
JAK/STAT mutations in BIA-ALCL. Establishing chronicity in the acquisition of novel
genetic mutations in BIA-ALCL remains a nascent area of research but could offer new
avenues for diagnosis and treatment of this complex disease.

Implant Texturization and Capsular Morphology
The introduction of implant texturization, a known modifiable risk factor for the
development of BIA-ALCL, improved implant stabilization on the chest wall while
similarly diminishing the rate of capsular contracture specifically in subglandular
augmentation. However, texturization brought unique challenges and complications,
including late seromas and a “double” capsule phenomenon not previously identified in
smooth textured implant counterparts.66 Given that BIA-ALCL is thought to arise from
the implant capsule, understanding the capsular biology is essential to understanding the
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pathogenesis of BIA-ALCL. Histologically, the capsule has relatively low cellularity and
consists of sparse inflammatory cells including macrophages and lymphocytes
interspersed with thick fibrous bands of collagen. Katzin et al. showed that benign
effusions and implant capsules from patients with textured-surface breast implants were
T-cell predominant, expressing CD3+ CD4+ CD29+ CD45RO-. CD29 (integrin beta-1)
is a cell surface receptor responsible for cellular adhesion and leukocyte homing.67 They
also found that implant-associated lymphocytes were commonly accompanied by silicone
laden foamy macrophages, which the authors argued provided strong evidence to support
the hypothesis that silicone-laden macrophages act as the antigen presenting cell to CD4+
T-cells, driving the immune response, cytokine release, further T-cell chemotaxis, and
cellular trafficking to implanted devices. Katzin et al. also observed that T-cell activation
occurred as early as one year after implantation and persisted up to 9 years, well within
median time to presentation of BIA-ALCL (8-10 years).37
Wolfram et al. characterized the cellular and molecular composition of benign and
contracted capsules from patients with silicone breast implants.68,69 While surface
texturization characteristics were not specified, their studies provided additional evidence
that silicone breast implants are capable of eliciting a strong Th1/Th17–weighted T-cell
immune response, with FoxP3+/CD25+ T regulatory cells (Treg) found within the
frontier layer of the fibrous capsule among the population of T effector cells. Of note,
Lechner found FoxP3 expression in the TLBR cell lines, whereas Di Napoli et al. found
that a proportion of BIA-ALCL showed a FoxP3+/CD25+ phenotype and a significant
enrichment in RORC1 and IL-17A transcripts, suggesting that BIA-ALCL tumor cells
may retain a phenotypical plasticity between Treg and Th17 cells.
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Although the cause of the T-cell activation in BIA-ALCL remains an area of
intense focus and debate, these data demonstrate that textured silicone breast implants are
capable of generating an early and sustained T-cell response which may be activated by
antigen-presenting, silicone-laden capsular macrophages (Figure 3-3). Taken together,
this may serve as the inciting event that promotes an inflammatory milieu and facilitates
malignant transformation.
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Figure 3-3. Silicone-laden “foamy macrophages” contained within the capsule of a
patient with a textured-surface breast implant.
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Emerging Theories on Pathogenesis
3.1.1

Biofilm theory

Previous research has implicated an LPS endotoxin from gram negative bacteria
inciting malignant transformation as a number of sarcomas and B cell lymphomas
originate from cancer-promoting bacterial-associated inflammatory pathways.70
Specifically, gastric MALT B-cell lymphoma arising from an inflammatory reaction to
H. pylori as an example. LPS endotoxin leading to BIA-ALCL, however, is an emerging
area of investigation. Research from Deva and colleagues has implicated breast implant
contamination with the development of capsular contracture71—an enhanced fibrotic
response to implanted foreign material. These data led Hu et al. to hypothesize BIAALCL tumorigenesis may occur as in response to any gram negative bacteria’s LPS
coat.12 However, LPS induced T-cell lymphomagenesis has no reported precedence.
Early investigations into the microbiome of BIA-ALCL implicated Ralstonia pickettii.
Interestingly, Ralstonia pickettii is a biofilm generator commonly found in water sources,
but it also occurs as a common laboratory contaminant, the latter of which has been
discussed in detail in the orthopedic literature.72,73 Walker et al. used 16S rRNA
sequencing to test the Ralstonia hypothesis and better define the microbiome of BIAALCL specimens (n = 8) and benign breast implant capsules from the contralateral
breast.14 Their study failed to replicate the Ralstonia spp. data previously described by
Hu and colleagues.12 Walker et al. demonstrated a gram-positive predominance and that
BIA-ALCL does not appear to have a distinct microbiome in comparison to normal
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capsules. Collectively, these data challenge the notion of a gram-negative shift, and
whether that has any role in pathogenesis.
Jacombs et al. studied breast implant surface characteristics and bacterial loads in
smooth versus textured-surface implants inoculated with Staphylococcus epidermidis and
found that texturized devices carried a bacterial load (1.8 x 108 bacteria/g) 20-times
greater than smooth (5.75 x 106 bacteria/g) in a porcine model.74 Intuitively, a greater
surface area of a textured implant holds a greater number of bacteria as a mere
consequence of higher physical capacity. While this finding highlights an important
difference between smooth and textured breast devices, it fails to provide a mechanism
by which an increased bacterial load could lead to BIA-ALCL formation. Although
evidence for a specific bacterial pathogen remains elusive, that does not preclude
involvement of an infectious agent. STAT3 activation as a result of a bacterial infection
has been shown to drive infection-associated cancers.75 In fact, aberrant JAK1/STAT3
signaling is highly involved in progression of H. pylori-induced gastric cancer.75 While
microbial data are conflicting, future investigations should seek to determine the ability
of opportunistic, breast implant-associated pathogens to induce JAK/STAT activation.

BIA-ALCL and JAK/STAT3
3.1.2

BIA-ALCL harbors oncogenic JAK/STAT3 mutations

Brody was among the first to suggest that genetics without a biofilm potentiator
may be central to the pathogenesis of BIA-ALCL and theorized that it may also partially
explain susceptibility to the disease.21 To date, oncogenic JAK-STAT3 pathway
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mutations have been described in 43.8% of successfully tested cases (Table 3-1). In a
landmark study, Blombery et al. utilized whole exome sequencing on DNA extracted
blood and peri-prosthetic effusions in two patients with pathologically confirmed BIAALCL.52 In the first case, the authors identified a somatic, oncogenic mutation in STAT3.
The STAT3 missense variant (p.S614R) leads to increased transcription of STAT3 which
has also been shown in other T-cell and NK cell lymphoproliferative disorders. In the
second case, somatic and germline missense variants were identified in JAK1 (G1079V)
and JAK3 (V772I), respectively. Interestingly, amino acid substitutions in JAK1 G1079V
have been observed in ALK-negative systemic ALCL. The JAK3 variant has been
observed in other peripheral-TCLs and NK cell lymphomas as well; however, the
significance of the variant is unclear as it has been shown to occur in the general
population at a frequency of 0.5-1% without an associated pathologic phenotype.
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Table 3-1. Next-generation sequencing data summary of JAK/STAT3 pathway
mutations in breast implant-associated anaplastic large cell lymphomas

Year Author

Sequencing Gene
type
panel
size

Utilization of
corresponding
healthy
controls

No. of
specimens
tested
successfully

2018

Blombery
et al.

TargetedNGS

180

No

2018

Oishi et al.

TargetedNGS
Letourneau Targetedet al.
NGS
Di Napoli Targetedet al.
NGS

5

No

9/9
(disregarding
two repeat
patients)
15/15

26

No

1/1

1/1 (100)

465

Yes

5/7

1/5 (20)

Blombery
et al.

20,000 Yes

2/2

2/2 (100)

2018
2016
2016

WES

No. of
specimens
harboring a
JAK/STAT3
pathway
mutation
7/9 (77.8)

4/15 (26.7)

JAK/STAT3, Janus kinase and Signal Transducer and Activator of Transcription Factor Three;
NGS, Next-Generation Sequencing; WES, Whole Exome Sequencing; No., Number.
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Other investigators have been able to use similar genetic sequencing techniques to
independently converge on candidate mutations in JAK/STAT implicated in the
development of BIA-ALCL. First, Di Napoli and colleagues utilized targeted-next
generation sequencing (NGS) (465-gene panel) on seven BIA-ALCL specimens and
identified oncogenic mutations in two separate cases.53 In the first case, dual oncogenic
STAT3 and suppressor of cytokine signaling 1 (SOCS1) mutations were discovered.
SOCS1 is an important negative regulator of the pathway that is capable of directly
inhibiting JAK.76 The observed SOCS1 mutation occurred as a result of a frame-shift
mutation that led to a premature stop codon in SOCS1 (p.P83Rfs*20). In their second
case, Di Napoli described the same missense STAT3 variant (p.S614R) first described by
Blombery and colleagues.52 In a follow-up study, Blombery et al. also performed
targeted-NGS (180-gene panel) on 11 BIA-ALCL specimens.51 Ten of the 11 cases
harbored a JAK-STAT3 pathway genetic variant. Seven out of the 11 cases contained a
STAT3 variant. Two cases with wild-type STAT3 contained an SOCS1 or an activating
JAK1 mutation. Oishi et al. used targeted-NGS (5-gene panel) on BIA-ALCL tumor
specimens (n = 15).16 Oncogenic JAK/STAT3 mutations were found in 26.7% (4/15) of
specimens. The same STAT3 variant (p.S614R) previously described by Blombery and
others was found in another case.52,53,77,78 Oishi et al. also discovered a novel STAT3
missense variant (Y640F) in two other cases.
While outside the scope of this review, the authors acknowledge that other nonJAK/STAT3 pathway genetic variants in TP5353,79–81 and DNMT3A53 have been
described in BIA-ALCL.
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3.1.3

BIA-ALCL tumors express STAT3 transcripts and activated STAT3
Although 73.3% of the specimens lacked a JAK/STAT mutation in the study by

Oishi et al., 100% of BIA-ALCL specimens tested to date have exhibited activated
STAT3 on immunohistochemistry. Lechner and colleagues developed and characterized
the first BIA-ALCL cell lines (TLBR 1-3).82,83 Immunoblotting revealed activation of
STAT3 across all cell lines, with the greatest activation in the most clinically advanced
case. These finding were confirmed in xenograft models showing similar gene expression
profiles. Di Napoli et al. investigated the gene-expression profiles of BIA-ALCL (n = 6)
compared to normal T-cells and other peripheral T-cell lymphomas.17 Gene set
enrichment analysis revealed that similar to systemic ALCL, BIA-ALCL tumor
specimens showed activation of STAT3 signaling and downregulation of the T-cell
receptor (TCR) pathway, suggesting the acquisition of an antigen-independent,
constitutively activated state. Our group compared the transcriptional profiles of BIAALCL tumor specimens using hybridization-based transcriptional profiling and found
that STAT3 was also differentially expressed in BIA-ALCL relative to healthy controls
(Figure 3-4).
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A.

B.

Benign Capsule

BIA-ALCL 1

BIA-ALCL 2

Figure 3-4. Differential STAT3 expression in BIA-ALCL.
(A) Upregulation of STAT3 mRNA expression in BIA-ALCL vs. benign breast
implant capsule; * p < 0.014 (B) Immunohistochemistry of phosphorylated
STAT3 in BIA-ALCL vs. benign breast implant capsules.
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3.1.4

STAT3 drives Th1/Th2/Th17 polarization and allergic inflammation
Kadin et al. and Di Napoli et al. suggest that BIA-ALCL tumors likely derive

from CD4+ memory activated T-cells with features of Th1/Th17.84 Importantly,
Th1/Th17 cells are antigen-driven memory T-cells that have been implicated in other
chronic inflammatory conditions including rheumatoid arthritis and psoriasis, as well as
cancer.85 Kadin and colleagues also reported that BIA-ALCL cells produce the Th2
cytokine IL-13, and variably express the Th2 transcription factor GATA3. These findings
support an antigenic stimulant in BIA-ALCL allergic in nature. Interestingly,
constitutively active STAT3 is known to induce a Th17 phenotype, but it is also required
for the expression of Th2-associated cytokines and transcription factors and the
development of allergic inflammation.86 Rastogi et al. recently integrated the biofilm
hypothesis with JAK/STAT signaling, claiming that a subclinical biofilm infection can
elicit chronic inflammation resulting in oncogenic transformation through a modified
Th1/Th17 cellular response or through oncogenic mutations in JAK-STAT.87 The authors
of the current paper tend to agree that malignant transformation in BIA-ALCL must
progress from chronic inflammation, thereby inducing a Th1/Th17 and Th2 response
which facilitates aberrant T-cell clonal expansion (Figure 3-5).
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Figure 3-5. Proposed mechanisms of BIA-ALCL tumorigenesis.
Interaction of an allergen, LPS endotoxin, particulate matter, or possibly on oncogenic
virus through an antigen presenting cell interacting with a naive CD4+ T-cell leads to a
chronic inflammatory state. The chronic immune response results in aberrant STAT3
signaling that may or may not facilitate activating STAT3 mutations in a feed forward
loop. An overabundance of STAT3 promotes the differentiation of Th1/Th17 as well as
Th2 lymphocyte phenotypes, ultimately leading to unregulated T-cell clonal expansion
and BIA-ALCL formation.
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3.1.5

IL-6/JAK/STAT3 signaling axis in BIA-ALCL
The IL-6/JAK/STAT3 signaling axis may explain pathogenesis in cases without a

driver gene mutation. As previously mentioned, IL-6 is the main cytokine activator of the
JAK/STAT3 pathway. While Lechner et al. showed that BIA-ALCL tumors highly
expressed IL-6, neutralization experiments failed to inhibit tumor proliferation
(unpublished data).82 The authors speculated that this may have occurred as a result of
high levels of IL-6 produced by tumor cells. Chen et al. interrogated cell lines from
several ALK-negative lymphoma subtypes including BIA-ALCL (TLBR 1/2).88
Abrogation of GP130, a subunit of IL-6R, induced tumor cell death even in the presence
of activating JAK1/STAT3 mutations in all cell lines except for BIA-ALCL. Despite high
levels of IL-6 and IL-6R expression, TLBR 1/2 cell lines remained viable. This suggests
that while cytokine receptor signaling is critical for most ALK-negative lymphomas,
BIA-ALCL may have other independent mechanisms for stimulating JAK/STAT3
expression, perhaps through growth factor mediated signaling or underlying genetic
mutations.
3.1.6

JAK/STAT inhibition induces tumor cell death
Lechner et al. showed that TLBR cell lines are subject to JAK-STAT inhibition.82

When treated in vivo with sunitinib, a JAK-STAT inhibitor, tumor cell death was induced
in a dose-dependent manner. Although more recent evidence-based treatment
recommendations call for complete surgical excision and implant removal in most cases,
JAK-STAT may serve as a novel therapeutic target in cases of advanced disease. 30–32,89 A
list of potential therapies targeting the JAK/STAT3 pathway is summarized in Table 3-2.
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Table 3-2. Potential therapies targeting IL-6/JAK/STAT3 pathway in BIA-ALCL
Drug Name

FDA Status

Indication

Mechanism of
Action

Notes

JAK Inhibitors
Ruxolitinib

FDA-approved

JAK 1,2 inhibition

Trials for HNSCC and BC

Tofacitinib

FDA-approved

Primary myelofibrosis,
Polycythemia vera,
GVHD
RA

JAK 3 inhibition

Studied in IBD and
psoriasis, increase risk of
lymphoma

Baricitinib
Upadacitinib

FDA-approved
FDA-approved

JAK 1,2 inhibition
JAK 1 inhibition

Fedratinib

FDA-approved

Moderate to severe RA
Moderate to severe RA
unresponsive to MTX
Primary or secondary
myelofibrosis

STAT3 Inhibitors
Atovaquone

FDA-approved

Downregulates
GP130

Pyrimethamine

FDA-approved

Antimicrobial for
malaria, toxoplasmosis,
PCP
Antimicrobial for
malaria and
toxoplasmosis

Cetuximab

FDA-approved

Pimozide

FDA-approved

HNSCC, NSCLC,
colorectal cancer
Antipsychotic

Monoclonal antibody
against EGFR
Dopamine antagonist

TTI-101

Phase 1 trial

Direct STAT3
inhibitor

IMX-110

Phase 2a trial

BC, HNSCC, NSCLC,
HCC, CRC, Gastric
cancer, Melanoma
Solid tumors,
Pancreatic cancer,
Breast cancer, Ovarian
cancer

Nanoparticle
encapsulating STAT3
inhibitor and lowdose doxorubicin

IL-6 Inhibitors
Bazedoxifene

FDA-approved

Osteoporosis
prevention

SERM, IL-6 and IL11 inhibitor

Synergistic effect with
temsirolimus in treatment
of osteosarcoma

Tocilizumab

FDA-approved

Humanized
monoclonal antibody
to IL-6R

Studied in ankylosing
spondylitis and systemic
lupus erythematosus

Siltuximab

FDA-approved

RA, Juvenile idiopathic
arthritis, Giant cell
arteritis, Cytokine
release syndrome
Castleman’s disease

Chimeric monoclonal
antibody to IL-6

Phase 2 studies for
prostate and ovarian
cancer

Sarilumab

FDA-approved

RA

JAK 2 inhibition

Competitively
inhibits DHFreductase

Human monoclonal
antibody to IL-6R

Other
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Black box warning for
serious encephalopathy

Attenuated breast cancer
tumor growth in murine
model, ongoing phase 2
trial for CLL and SLL

Anticancer effects on
osteosarcoma, leukemia,
breast cancer, melanoma

Brentuximab
vedotin

FDA-approved

Crizotinib

FDA-approved

ALCL, Hodgkin
lymphoma, mycosis
fungoides
NSCLC

Chimeric monoclonal
antibody to CD30
Inhibits ALK

Antibody-drug conjugate
that delivers MMAE to
CD30+ cells
Multiple clinical trials for
ALCL and advanced solid
tumors

IL-6, Interleukin six; IL-11, Interleukin eleven; BC, breast cancer; HNSCC, head and neck squamous
cell carcinoma; NSCLC, non-small cell lung carcinoma; SCC, squamous cell cancer; HCC,
hepatocellular carcinoma; CRC, colorectal cancer, IL-6R, IL-6 receptor; RA, Rheumatoid Arthritis;
SERM, selective estrogen receptor modulator, PCP, pneumocystis carinii pneumonia; MMAE,
monomethyl auristatin E.
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Conclusions
Recent molecular studies have expanded the concept that aberrant JAK/STAT3
signaling may be a critical component in BIA-ALCL tumorigenesis and progression and
may provide a novel therapeutic target for select patients. As such, larger, comprehensive
oncogenomic studies are needed to better define the genetic landscape of BIA-ALCL, the
frequency at which JAK/STAT3 pathway mutations occur, and their functional
significance.
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CHAPTER 4. BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL
LYMPHOMA: AN EVIDENCE-BASED SYSTEMATIC REVIEW
Abstract
Objective: The authors introduce breast implant-associated anaplastic large cell
lymphoma (BIA-ALCL) as a relevant, emerging disease through the epidemiology,
pathophysiology, and clinical outcomes that have come to inform the current federal
regulatory climate surrounding textured breast devices. This evidence-based systematic
review synthesizes and critically appraises current clinical recommendations and
advances in the diagnosis and treatment of BIA-ALCL. This review also aims to broaden
physician awareness across diverse specialties, particularly among general practitioners,
breast surgeons, surgical oncologists, and other clinicians who may encounter patients
with breast implants in their practice.
Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is
an emerging and treatable immune cell cancer definitively linked to textured-surface
breast implants. Although National Comprehensive Cancer Network (NCCN) consensus
guidelines and other clinical recommendations have been established, the evidence
supporting these guidelines has not been systematically studied. The purpose of this
evidence-based systematic review is to synthesize and critically appraise current clinical
guidelines and recommendations while highlighting advances in diagnosis and treatment
and raising awareness for this emerging disease. Methods: This evidence-based
systematic review evaluated primary research studies focusing on the diagnosis and
treatment of BIA-ALCL that were published in PubMed, Google Scholar, and other
scientific databases through March 2020. Results and Conclusions: The clinical
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knowledge of BIA-ALCL has evolved rapidly over the last several years with significant
advances in diagnosis and treatment, including en bloc resection as the standard of care.
Despite a limited number of high-quality clinical studies comprised mainly of Level III
and Level V evidence, current evidence aligns with established NCCN consensus
guidelines. When diagnosed and treated in accordance with NCCN guidelines, BIAALCL carries an excellent prognosis.

Background
Breast implants are used extensively in the United States and throughout the
world for breast augmentation and breast reconstruction. Textured-surface breast
implants, a common type of breast implant, have been linked to breast implant-associated
anaplastic large cell lymphoma (BIA-ALCL), an emerging non-Hodgkin type T-cell
lymphoma.90 While BIA-ALCL shares morphologic and immunophenotypic
characteristics similar to other anaplastic large cell lymphomas, specifically anaplastic
lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL), its
presentation, diagnosis, and clinical course represent a novel clinical entity with unique
challenges for medical practitioners.
Since first being described in the mid to late ‘90s,2,47,91,92 over 800 cases have
been confirmed worldwide.42 The majority of cases present with an acute onset, unilateral
periprosthetic effusion, and follow an indolent clinical course when diagnosed and treated
promptly.37 When practitioners misdiagnose, fail to diagnose, or do not adhere to clinical
guidelines, disseminated disease and death have resulted.93 Reported cases of BIA-ALCL
stratify equally between cosmetic and reconstructive patients, suggesting that history of a
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previous malignancy, such as breast cancer, is not an independent risk factor for the
development of the disease. However, reports of implant-associated blood cancers
continue to surface following reconstructive or cosmetic surgeries with textured
devices,8,94 implicating textured implants in the pathogenesis of this rare disease, while
similarly raising concerns about the long-term safety of textured devices.35,95 Despite
some of these concerns, Tandon et al. found that the use of textured breast implants for
cosmetic indications is increasing.96 In 2017, approximately 70,000 textured breast
implants were placed in the U.S., accounting for 12.5% of the total market share.97 In
contrast, textured breast implants accounted for nearly 90% of device preference
throughout Europe and Australia.6 As such, there are currently millions of women
worldwide with textured-surface breast implants, which poses a significant health risk for
patients exposed to this type of device.
In 2011, the U.S. Food and Drug Administration (FDA) issued a safety
communication about the possible association between breast implants and BIA-ALCL.98
Shortly thereafter, the World Health Organization provisionally classified BIA-ALCL as
a distinctly challenging clinical entity.25 Out of that concern, nearly forty different
countries have banned the use of Allergan Biocell (Dublin, Ireland) textured-surface
breast implants, and France has banned the use of macrotextured devices altogether. 99
Following worldwide bans, the U.S. FDA called for a Class 1 device recall.
Subsequently, Allergan issued a voluntary, worldwide recall of their textured-surface
breast implants and textured-surface tissue expanders.44,100 Allergan’s “salt-loss”
manufacturing technique creates an exceptionally coarse macrotextured surface that
maximizes tissue ingrowth in order to maintain breast pocket stability and improve
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aesthetic outcomes. However, this same process has come under scientific scrutiny, as
Allergan carries the highest manufacturer-specific risk (1:355 - 2,207 patients) for the
development of BIA-ALCL.4,101 Other device companies employ different texturing
techniques that result in less rugged surfaces, including the Mentor corporation (Irvine,
CA), which have allowed textured breast devices to remain commercially available in the
U.S., despite their association with BIA-ALCL. Mentor specifically uses a negativeimprint stamping technique that carries significantly lower risk estimates (1:86,029
implants; 95% CI: 15,440 – 1,301,759) for the development of lymphoma in the
Australia-New Zealand cohort which translates to an increased risk of 27.1:1 for Allergan
Biocell implants compared to Mentor Siltex implants.3 At this time, considerable clinical
debate exists over the best course of action to both identify at-risk individuals with
textured devices and adequately protect these patients from disease development while
further preventing all future cases of BIA-ALCL. Despite recognition as a distinct
clinical entity, BIA-ALCL remains underdiagnosed given its subtle clinical presentation
and lack of physician awareness of the disease.
Evidence-based medicine is an applied methodology that utilizes the best,
currently available evidence to guide clinical decision-making and care of individual
patients in order to optimize patient outcomes. Although consensus guidelines and
clinical recommendations have been put forth regarding diagnosis and treatment, the
evidence supporting those recommendations has not been systematically studied. The
purpose of this evidence-based systematic review is to detail and critically evaluate
current practice recommendations for the effective diagnosis and management of BIAALCL in order to improve missed or misdiagnoses, increase reporting of affected
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individuals, and to determine if current treatment guidelines are supported by highquality evidence. This study also aims to increase physician awareness of this emerging
disease, particularly among breast surgeons, surgical oncologists, and other clinicians
who may encounter patients with breast implants in their practice.

Methods
4.1.1

Search strategy
A systematic review of PubMed (MEDLINE), EMBASE, Google Scholar, Web

of Science, the Cochrane library, and the grey literature was conducted between March 115, 2020. The following search terms and Medical Subject Headings (MeSH) were used
in combinations with Boolean operators: breast implant associated-anaplastic large cell
lymphoma, breast implant, breast implants, lymphoma, treatment, and diagnosis.
4.1.2

Inclusion and exclusion criteria
Study inclusion criteria consisted of patient-oriented primary research related to

the diagnosis and treatment of BIA-ALCL. Review articles were included on a case-bycase basis dependent on the ability to provided novel insights, including advancements or
changes in diagnosis and treatment not discussed in a primary article. Editorials,
discussions, and case reports were excluded. Citation chaining was performed on articles
that met inclusion criteria using Web of Science. Two independent reviewers screened
(R.C.D., M.W.C.) titles, abstracts, and the text of identified articles. Disagreement
between reviewers was handled through discussion until there was 100% agreement.
Only articles in the English language were reviewed. The search strategy was designed to
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capture articles focused on the diagnosis and treatment of BIA-ALCL. The list of
references was reviewed for relevant studies, and no additional articles were discovered
as a result. Each study was assessed for potential sources of bias. Levels of evidence were
assigned, and articles related to current treatment recommendations (e.g., en bloc
resection, chemotherapy, radiation therapy, breast reconstruction) were ranked using the
American Society of Plastic Surgeons (ASPS) Evidence-Based Rating Scales for
Therapeutic Studies (Table 4-1). This systematic review was conducted in accordance
with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
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Table 4-1. American Society of Plastic Surgeons Evidence-Based Rating Scale for
Therapeutic Studies
Level of
Evidence

Description

I

High-quality, multi-centered or single-centered, randomized
controlled trial with adequate power; or systematic review of
these studies

II

Lesser-quality, randomized controlled trial; prospective cohort or
comparative study; or systematic review of these

III

Retrospective cohort or comparative study; case-control study; or
systematic review of these studies

IV

Case series with pre-/post-test; or only post-test

V

Expert opinion developed via consensus process; case report or
clinical example; or evidence based on physiology, bench
research or “first principles”
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Results
An overview of the search strategy is provided in Figure 4-1. The initial search
yielded 511 articles. No other articles were identified from other sources. After removing
duplicates found in the search (n = 3), 508 articles remained. Titles and abstracts were
reviewed (n = 508) for relevance, and as a result, 501 articles were excluded on the basis
of study design and lack of primary evidence related to diagnosis or treatment. The
remaining articles (n = 7) were reviewed in their entirety and met inclusion criteria
(Table 4-2). Studies were comprised of level III (n = 3) and level V (n = 4) evidence that
focused on the diagnosis and treatment of BIA-ALCL. The limited number of available
studies and heterogeneity in reported data precluded any meta-analysis.
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Figure 4-1. Schematic of search strategy
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Table 4-2. Cohort Studies and Consensus Guidelines of Breast Implant-Associated
Anaplastic Large Cell Lymphoma
Authors
Reference
Year
Study
Focus of
Level of
design
article
evidence
Clemens
et al

Complete Surgical
Excision Is Essential for
the Management
of Patients with Breast
Implant–Associated
Anaplastic
Large-Cell Lymphoma

2016

Retrospective

Surgical
Resection/

III

Tevis et al

Stepwise En Bloc
Resection of Breast
Implant-Associated
Anaplastic Large Cell
Lymphoma with
Oncologic
Considerations

2019

Retrospective
cohort

Surgical
Resection

III

Lamaris
et al

Breast Reconstruction
Following Breast
Implant-Associated
Anaplastic Large Cell
Lymphoma

2019

Retrospective
cohort

Breast
Reconstruction

III

Clemens
et al

How to Diagnose and
Treat Breast Implant
Associated Anaplastic
Large Cell Lymphoma

2018

CME

Diagnosis and
Treatment

V

MehtaShah et al

How I Treat Breast
Implant Associated
Anaplastic Large Cell
Lymphoma

2018

Review

Diagnosis and
Treatment

V

Clemens
et al

2019 NCCN Consensus
Guidelines on the
Diagnosis and
Treatment of Breast
Implant-Associated
Anaplastic Large Cell
Lymphoma (BIAALCL)

2019
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Epidemiology
Historically, rare diseases present epidemiological challenges for investigators;
precisely estimating the true incidence of disease remains an elusive task. With respect to
BIA-ALCL, existing epidemiological studies are limited by a lack of global reporting and
incomplete breast implant sales data, making it similarly difficult to quantify an accurate
risk assessment.39 The current lifetime risks associated with the development of BIAALCL vary significantly according to geography and are also manufacturer specific. 102
The Australian Therapeutic Goods Administration estimates a lifetime risk of 1:2,500 1:25,000 patients with a textured breast implant.45 More recent work by Doren et al.
estimates an average lifetime prevalence across manufacturers of 1:30,000 patients with a
textured breast implant in the U.S.3 Interestingly, the authors’ reported a nearly six-fold
increase in the lifetime prevalence of BIA-ALCL cases attributable to Allergan textured
devices compared to textured devices from other manufacturers. These data were later
cited by the FDA as partial reasoning for issuing the Class 1 recall.103 Allergan’s unique
manufacturing process highlights the texturing process as a critical regulator of disease
pathogenesis. As such, investigators have focused on understanding the innate and
adaptive immune response to implanted devices in hopes that their efforts will yield a
clearer understanding of the cellular and molecular mechanisms driving disease
development.

Pathophysiology
BIA-ALCL is a subset of systemic anaplastic large cell lymphomas (sALCL),
which are a class of non-Hodgkin type peripheral T-cell lymphomas. Investigators
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stratify sALCLs by cellular and molecular markers that carry either favorable or less
favorable clinical outcomes. The presence of anaplastic lymphoma kinase (ALK+) occurs
in 60-80% of sALCLs and carries a favorable 5-year progression-free survival. The other
20-40% of ALK- sALCLs are characterized by specific gene rearrangements—Dusp22,
TP63, or Triple Negative (ALK-, Dusp22-, TP63-) and carry an overall survival rate of ≤
50%.104 BIA-ALCL cells isolated from patients are classified as Triple Negative
ALCLs.16 Although, reports exist of diffuse large B-cell lymphomas, marginal zone Bcell lymphoma, and plasmacytomas occurring adjacent to textured-surface breast
implants, suggesting that the disease may have a broad spectrum of genotypic and
phenotypic variations.105,106 BIA-ALCL cells also carry the CD30 cell surface marker that
traditionally marks activated B- and T-cells. Therefore, BIA-ALCL cells are
pathologically classified as CD30+, ALK- lymphoma cells.
After two decades of investigation, the biological basis of the disease remains
poorly understood.19 Current evidence suggests BIA-ALCL arises from a novel antigenic
stimulus that induces a chronic inflammatory state.1,11 Consistent exposure to
inflammatory cytokines in a genetically susceptible individual ultimately leads to
unregulated immune-cell clonal expansion and lymphomagenesis. However, the specific
antigenic stimulus remains a controversial topic and is the focus of our laboratory and
others. Early investigations identified a gram-negative bacillus, Ralstonia pickettii, in
establishing a subclinical, periprosthetic biofilm, leading to a lipopolysaccharide (LPS)
endotoxin-induced carcinogenesis.12 After a more careful examination, the Ralstonia data
have since been refuted, and currently, no clear association between the breast
microbiome and BIA-ALCL pathogenesis exists.14 Other investigators have focused on
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allergen-driven carcinogenesis, either from particulate matter from the operating suite
landing on implant surface or aberrant activation of the aryl hydrocarbon receptor by the
contaminants residing on the implant surface itself.22,63,64 Genetics, in combination with
other factors, is also thought to be a major risk factor for the disease,20,107 with oncogenic
mutations in TP53,53,79,80,108 DNMT3A53, and the JAK-STAT3 pathway being
described.16,51–54 Other proposed oncogenic drivers may include viruses or chronic
trauma to the breast pocket.17,21 Nevertheless, evidence to support a unifying theory has
remained elusive, and the complex interplay between these factors remains largely
unknown.

Natural History and Spectrum of Disease
Early reports suggested two distinct histologic subtypes of BIA-ALCL, in situ
disease and infiltrative disease, each of which carried a significantly different prognosis.
Over time, the knowledge of the disease has evolved to encompass a spectrum of disease
that spans multiple diverse disease environments, including effusion-limited disease,
superficial capsular involvement, a grossly identifiable lesion, lymph node extension, and
finally, distant metastasis. In situ or effusion-limited disease is confined within the breast
implant capsule and is characterized by a lymphomatous cell layer on the luminal
capsular surface with or without suspension of anaplastic lymphoma cells in the serous
fluid. The infiltrative subtype extends into or beyond the fibrous capsule and may be
associated with locoregional or distant metastasis. The infiltrative subtype carries an
inferior prognosis.
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Clinical Presentation
The majority (80%) of patients present with a spontaneous delayed seroma
formation (greater than 1-year following implantation) but can also present with
lymphadenopathy (4 -12%) or a palpable mass (8 – 24%). Less frequently (< 5%), the
disease may present with local or systemic symptoms, including fever, capsular
contracture, or cutaneous manifestations. The median interval time to presentation is 7-10
years (range 1-28 years) following textured device implantation for breast augmentation
or reconstruction. Left untreated, scant CD30+, ALK- cells contained within the seroma
fluid may coalesce and acquire characteristics of solid tumors 26,40—including distant
metastasis—underscoring the importance of early diagnosis and intervention.

Diagnosis
The National Comprehensive Cancer Network (NCCN) guidelines for the
diagnosis and treatment of BIA-ALCL were established based on the current
understanding of the literature. In the subsequent paragraphs, we will discuss and
critically appraise the clinical data that coalesced to form these essential guidelines while
highlighting advances in diagnostic and therapeutic strategies and addressing current
controversies not covered in NCCN guidelines.
4.1.3

Differential diagnosis and diagnostic work-up
Generally, BIA-ALCL follows an indolent clinical course and has an excellent

prognosis when diagnosed and treated promptly. A proposed diagnostic algorithm is
outlined in Figure 4-2. Briefly, suspicious seromas should be drained using ultrasound64

guided fine-needle aspiration or in consultation with interventional radiology. It is
important to note that the peri-implant space around most implants contains only a trace
amount (5-10 mL) of fluid. Thus, an independent finding in an otherwise asymptomatic
patient does not warrant further investigation. After excluding other differential
diagnoses of delayed seroma (e.g., infection, isolated trauma to the chest wall), aspirate
(minimum 50 mL) should be sent for cytopathology with the request to “rule out BIAALCL.” A BIA-ALCL rule out requires three specific areas of investigation— CD30+
cells by immunohistochemistry, cellular atypia as assessed with microscopy and flow
cytometry to assess for T-cell clonality.32,89,109,110 Positive samples must typically satisfy
all of the three requirements: CD30+ cells in the aspirate; noted cellular atypia; and T-cell
clonality (Figure 4-3).
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Figure 4-2. Evidence-based diagnostic algorithm for BIA-ALCL.
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Figure 4-3. BIA-ALCL Lymphoma Cells
A malignant effusion in a BIA-ALCL patient demonstrates large pleomorphic anaplastic
cells with prominent horseshoe-shaped nuclei and nuclear folding. (hematoxylin stain,
500X magnification) Positive anaplastic cytology, CD30 immunohistochemistry
expression, and single T cell clonality demonstrated on flow cytometry are required for
BIA-ALCL diagnosis. Reprinted with permission by Clemens, MW, DeCoster, RC,
Fairchild, et al., 2019. Finding Consensus After Two Decades of Breast ImplantAssociated Anaplastic Large Cell Lymphoma Semin Plast Surg. 33(4):270-278, Thieme
Medical Publishers, Georg Thieme Verlag KG.
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While CD30 expression is a fundamental diagnostic element of BIA-ALCL,
isolated expression is not pathognomonic for establishing the diagnosis, as CD30 is also
expressed on other immune cells, including activated T- and B-cells, eosinophils, and
macrophages. Thus, CD30+ lymphocytes with otherwise normal morphology do not
require further investigation. Histologic experiments to assess cellular atypia focuses on
identifying cells with anaplastic features—pleomorphic nuclei, either heterochromic or
hyperlobulated, and abundant cytoplasm presenting in dense cellular sheets. These cells
are often “hallmark” cells of ALCL. T-cell clonality suggests T-cell receptor (TCR) gene
rearrangement in response to a single antigenic stimulus. Thus, if a single peak appears in
CD30+ flow cytometry, further investigation is warranted. As referenced earlier, the
combination of these three characteristics, CD30+ cells, exhibiting cellular atypia, and
TCR clonality, is highly suspicious for BIA-ALCL and should prompt clinical
intervention.
4.1.4

Diagnostic imaging
Ultrasound remains the imaging modality of choice for detecting a BIA-ALCL

related effusion or mass. Adrada et al. found that ultrasound conveys an 84% sensitivity
and a 75% specificity for detecting an effusion and is 46% sensitive and 100% specific
for detecting a mass.111 Equivocal results on ultrasound should be further investigated
with magnetic resonance imaging. The role of positron emission tomography-computed
tomography (PET-CT) for preoperative workup and tumor surveillance is discussed in
further detail below (see oncologic surveillance).
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4.1.5

Pathologic processing of specimens
In a proposed update to the College of American Pathologist policy on surgical

specimen collection, Lyapichev et al. recently developed a standardized protocol for
handling and processing BIA-ALCL tumor specimens.28 Using mathematical modeling,
the authors formulated an equation [minimum number of samples = 3.6 + 106.8/
(coverage%)] that can be used to determine the minimum number of sections required to
identify 95% of randomly distributed lesions in patients that do not have grossly
identifiable lesions. The formula translates into a requirement of 12 biopsies per capsule,
two for each side of the face of a cube. A more standardized protocol for the handling,
sampling, and reporting of BIA-ALCL cases will continue to improve diagnostic
accuracy and advance the collective understanding of the mechanisms underpinning this
complex disease by providing more generalizability and statistical power to future
studies.
4.1.6

Pathologic staging and prognosis
Although the Lugano modification (Ann Arbor staging system) has traditionally

been used to stage non-Hodgkin lymphomas, BIA-ALCL displays behaviors most similar
to solid tumors. Clemens et al. demonstrated that the TNM staging system more
accurately predicted overall survival and recurrence of BIA-ALCL than the Ann Arbor
staging system (p = 0.01).30 The TNM staging system for BIA-ALCL is summarized in
Table 4-3. Furthermore, Clemens et al. demonstrated a 91% five-year overall survival
rate and a five-year event-free survival rate of 49%.30 As previously mentioned, overall
and event-free survival increase with the use of complete surgical excision when
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compared to other treatment modalities (p < 0.001). Additionally, when comparing
prognosis according to stage, patients receiving complete surgical resection had an event
rate of 0% for stages T1, T2, and 14% at stage T4 (p < 0.001). Taken together, these data
strongly suggest that en bloc resection combined with early detection yields a better
early-term prognosis accompanied by a substantial survival benefit.
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Table 4-3. TNM Staging System for BIA-ALCL
TNM/Stage Classification
Primary tumor (T)
T1
T2
T3
T4
Regional lymph nodes (N)
N0
N1
N2
Distant metastasis (M)
M0
M1

Description
Confined to effusion or a layer on luminal side of capsule
Early capsule infiltration
Cell aggregates or sheets infiltrating the capsule
Lymphoma infiltrates beyond the capsule
No lymph node involvement
One regional lymph node (+)
Multiple regional lymph nodes (+)
No distant spread
Spread to other organs/sites

Stage
1A
1B
1C
IIA
IIB
III
IV

T1N0M0
T2N0M0
T3N0M0
T4N0M0
T1-3N1M0
T4N1M0
T (any) N (any) M1
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Treatment
Due to the emerging nature of this complex disease, a multidisciplinary team of
plastic surgeons, surgical oncologists, and pathologists should be assembled following a
definitive diagnosis of BIA-ALCL. The subsequent sections outline in detail evidencebased treatment strategies for achieving complete resolution. An overview of the
treatment algorithm is provided in Figure 4-4.
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Figure 4-4. Evidence-based treatment algorithm for BIA-ALCL
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4.1.7

Surgical management

4.1.7.1 Preoperative workup
Following the establishment of a BIA-ALCL diagnosis, a team of
multidisciplinary experts consisting of a medical oncologist, surgical oncologist,
radiation oncologist, pathologist, and the plastic surgeon should be assembled. A list of
suggested laboratory testing based on the current understanding of the reported cases is
summarized in Table 4-4. PET/CT should be considered preoperatively to assess for
capsular masses or extension into the chest wall and can serve as a “roadmap” to guide
oncologic resection. However, the role of PET-CT in evaluating local disease
immediately following (2 -3 months) tumor extirpative surgery may be diminished as a
result of surgery-induced inflammation.
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Table 4-4. Suggested preoperative laboratory testing
Test
Complete blood count with
differential

Comments

Complete metabolic panel
Lactate dehydrogenase (LDH)

Order LDH and Hep B if chemotherapy is being
considered

Hepatitis B (Hep B)
Bone marrow biopsy

Order if high suspicion of advanced disease
(locally aggressive or lymph node metastasis)

PET/CT

Used to assess for chest wall involvement and
to guide surgical resection
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4.1.7.2 En Bloc resection
Clemens et al. compared different therapeutic approaches and assessed oncologic
outcomes in 87 patients with BIA-ALCL.30 The authors found that complete surgical
excision (e.g., complete capsulectomy) demonstrated long-term, disease-free survival
compared to all other therapeutic modalities (p = 0.001). As a result, current National
Comprehensive Cancer Network (NCCN) consensus guidelines call for en bloc surgical
resection of the surrounding capsule and removal of the implant (Figure 4-5).32 It is
important to note that 2 - 4% of BIA-ALCL cases present with bilateral disease.
Therefore, removal of the contralateral implant with complete capsulectomy should be
considered should symptoms warrant. Tevis et al. outlined the steps for en bloc resection
and processing with all relevant oncologic considerations.33 Given that BIA-ALCL does
not involve the breast parenchyma, mastectomy is not indicated.
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Figure 4-5. En bloc surgical resection and device explantation.
The capsule and implant of a BIA-ALCL patient are shown during evaluation by
pathology. Note the thickened surface of the capsule which had developed into a mass.
Reprinted with permission by Clemens, MW, DeCoster, RC, Fairchild, et al., 2019.
Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large
Cell Lymphoma Semin Plast Surg. 33(4):270-278, Thieme Medical Publishers, Georg
Thieme Verlag KG.
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For asymptomatic patients concerned about the potential risk of developing BIAALCL, there is currently no evidence to support prophylactic implant removal as the risks
associated with the required surgical procedure outweighs the current risk of BIA-ALCL
development. This does, however, bring up an important issue. In the asymptomatic
patient with a textured surface implant who wants the device removed out of concern of
developing BIA-ALCL, is a total capsulectomy warranted? Complete capsulectomy
remains an exceedingly challenging surgical procedure, which carries its own risks, such
as additional bleeding and an increased risk of pneumothorax—specifically due to the
strong adherence of the posterior wall of the capsule to the chest wall. Currently, there is
insufficient clinical evidence to suggest the selection of subtotal versus total
capsulectomy. Although the evidence supports a capsular origin of BIA-ALCL, there is
not enough evidence at this time to definitively establish complete capsulectomy as a
risk-reducing procedure in the asymptomatic patient. This concept marks an important
distinction between complete capsulectomy and en bloc resection, where the goal of the
latter is to achieve clear margins, something not obtainable in the patient where the
disease is not clinically evident. Nevertheless, the patient and surgeon should engage in a
meaningful discussion to consider the patient’s desire as well as the specific risks and
benefits for each approach on a case-by-case basis.
4.1.8

Indications for adjuvant therapies
The use of adjuvant chemotherapy or radiation in surgically unresectable or

advanced disease is backed by Level III evidence.30 Current NCCN guidelines advocate
for the use of brentuximab vedotin, a monoclonal antibody directed against CD30 or a
combination anthracycline-based chemotherapeutic regimen, CHOP (cyclophosphamide,
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adriamycin, vincristine, and prednisone), which is reserved for cases of residual or
disseminated disease (MD Anderson Stage IIB-IV).32 Radiation therapy (24 – 36Gy)
should be considered for patients with local residual disease, positive margins, or
surgically unresectable disease with chest wall extension and carries the same level
clinical of evidence.
As mentioned, the current therapeutic regimen was born out of necessity to handle
cases where en bloc resection is not achievable. The role of targeted therapies remains
under consideration. For example, recent work from our group and others has identified
aberrant JAK-STAT3 pathway involvement, which may serve as a novel therapeutic
target for JAK-STAT inhibitors in the future. To that end, prospective studies are needed
to further delineate the most effective chemotherapeutic regimen in the case of
disseminated disease.
4.1.9

Breast reconstruction after BIA-ALCL
Practitioners can reasonably offer immediate or delayed breast reconstruction

after oncologic resection for BIA-ALCL to most patients, given the favorable prognosis
of the disease with appropriate management. Methods of breast reconstruction after
device explantation and complete surgical resection include implant replacement,
autologous tissue transfer, mastopexy, or serial fat grafting. Given the known association
of ALCL with textured implants, it is strongly recommended that implant-based
reconstruction proceeds with smooth, round silicone implants should implant
reconstruction, so be desired. Although patients may be reluctant to pursue implantbased reconstruction given the anxiety of device-induced recurrence, evidence has
consistently demonstrated that all confirmed cases of BIA-ALCL have only occurred
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with textured devices.34 However, psychologic fear should be explored preoperatively as
the aforementioned options of autologous tissue transfer, mastopexy, or fat grafting
demonstrate similar patient satisfaction and clinical outcomes in breast reconstruction and
should remain as viable reconstructive options.
The timing of reconstruction after treatment has been highly debated and depends
on disease severity at presentation. Lamaris et al. proposed a treatment algorithm based
on their experience reconstructing 18 consecutive patients after treatment for BIAALCL.34 Patients with surgically resectable disease (stage IA-IC) can be offered either
immediate reconstruction or delayed reconstruction after surveillance PET/CT in 3-6
months. Complete capsulectomy can result in devascularized tissue and must be
considered in any patient undergoing immediate reconstruction. Those patients with
advanced disease (stage IIA-IV) should be offered delayed reconstruction after
surveillance imaging, which generally occurs 6-12 months after completion of surgical
resection and any adjuvant chemotherapy.
4.1.10 Oncologic surveillance
Patients that have been successfully treated should be followed by an oncologist
every 3-6 months for a period of two years.31 Follow up should include a physical
examination, and physicians may elect to use CT or PET/CT of the chest/abdomen/pelvis
to monitor for tumor recurrence.
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Insurance coverage
Insurance coverage for BIA-ALCL is provided by some major carriers, including
Blue Cross and Aetna. Coverage includes removal of the implant with capsulectomy out
of medical necessity, one indication being BIA-ALCL. A comprehensive list of ASPS
Insurance Coverage Criteria for Third-Party Payers-BIA-ALCL may be found on the
following website: (https://www.plasticsurgery.org/documents/HealthPolicy/Reimbursement/Insurance-2017-BIA-ALCL.pdf). Relevant diagnostic and
procedural codes are included in Table 4-5.
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Table 4-5. Relevant International Classification of Diseases, Tenth Revision, and
Current Procedural Terminology Codes for Suspected and Confirmed BIA-ALCL
Cases
Code
ICD-10 diagnostic codes
C84.79

N63

R59.9
N64.4
CPT procedural codes
10022
19101
19260
19328
19371
38525

Description
Anaplastic large cell lymphoma kinase-negative,
extranodal, solid organ sites
Unspecified lump in breast, nodule, mass, or swelling of
the breast
Enlarged lymph node
Other specified disorders of the breast
Fine needle aspiration with imaging guidance
Breast biopsy, open, incisional
Excision of chest wall tumor
Removal intact mammary implant
Breast periprosthetic capsulectomy
Biopsy/excision, lymph node; open or deep axilla

International classification of disease-tenth Revision, ICD-10; Current procedural
terminology, CPT.
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Disease reporting
All suspected or confirmed cases should be reported to the American Society of
Plastic Surgeons/Plastic Surgery Foundation Patient Registry and Outcomes For Breast
Implants and anaplastic large cell lymphoma (ALCL) etiology and Epidemiology
(PROFILE) registry (https://www.thepsf.org/research/registries/profile/case-submission).
The PROFILE registry now recognizes 288 confirmed or suspected cases in the U.S.,
bringing the total worldwide cases to 871 as of December 6th, 2019.112

Conclusions
The clinical knowledge of BIA-ALCL has advanced rapidly over the last several
years. This evidence-based systematic review critically evaluated current NCCN
consensus guidelines and clinical recommendations while highlighting advances related
to the diagnosis and treatment of BIA-ALCL, including en bloc resection as the standard
of care in the majority of cases. Despite a limited number of high-quality studies, current
clinical recommendations and NCCN consensus guidelines are supported by evidence
and represent best clinical practices. As reinforced throughout this article and in
conjunction with NCCN guidelines, early diagnosis, and strict adherence to clinical
guidelines maintain an excellent prognosis for patients diagnosed with the disease. For
the asymptomatic patient with a textured breast implant, there is currently no evidence to
support prophylactic removal, as performing removal in conjunction with complete
capsulectomy may not be a risk-reducing procedure. As the incidence of BIA-ALCL
continues to increase, prospective studies are needed to further delineate the most
effective diagnostic algorithms and treatment strategies. Finally, well-designed
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epidemiologic studies are needed to more accurately quantify the risk of BIA-ALCL for
patients considering breast augmentation or breast reconstruction with a textured-device
in order to better understand both the risk and benefits in order to improve patient safety.
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CHAPTER 5. CURRENT RISK OF BREAST-IMPLANT ASSOCIATED
ANAPLASTIC LARGE CELL LYMPHOMA: A SYSTEMATIC REVIEW OF
EPIDEMIOLOGICAL STUDIES
Abstract
Background: Recent epidemiological studies have attempted to accurately determine the
risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). However,
comparisons of previously published works are difficult due to widespread variations in
reporting. We systematically review the epidemiology in order to better define the current
risk of BIA-ALCL. Herein, we report the global epidemiology with an emphasis on the
U.S. breast implant population while simultaneously assessing the oncologic safety of
smooth-surface devices. Methods: A systematic review of PubMed and other scientific
databases, as well as the grey literature, was conducted for epidemiologic studies on BIAALCL. Using analytical and descriptive epidemiology, we estimated the cumulative
incidence and incidence rate of BIA-ALCL using a standardized approach. Cumulative
incidence was reported at implant and patient-specific levels. Results: The patientspecific cumulative risk within the U.S. market ranges from 1.79 per 1000 (1:559) to 2.82
per 1000 (1:355) patients with a textured implant. The implant-specific risk of Allergan
textured devices ranges from 1:602-871 to 1:8500, while the risk of commercially
available Mentor Siltex implants is 1:50 000. No epidemiological study or regulatory
agency reported a case of BIA-ALCL occurring exclusively with a smooth device.
Conclusions: With the removal of Allergan textured breast devices, this study
demonstrates substantial gaps in the epidemiological knowledge of BIA-ALCL, including
the current risk of commercially available textured breast implants in the U.S. market.
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Although the risk of BIA-ALCL is low, surgeons should exercise extreme caution when
considering the use of a textured breast device for cosmetic or reconstructive purposes.

Background
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a novel
T-cell lymphoma associated with textured-surface breast implants.1,41,90 Under most
circumstances, BIA-ALCL presents as an acute-onset, periprosthetic fluid collection
greater than 1-year following device implantation.37 National Comprehensive Cancer
Network consensus guidelines advocate for device explantation and complete surgical
excision as the standard of care.30,32 Adjuvant therapy, including chemotherapy and
radiation, are reserved for patients with advanced or refractory disease. Although the
biological mechanisms remain largely unknown, texturization is thought to play a critical
role in the malignant transformation of the disease.102 Some authors have suggested that
the aggressive surface texturing characteristics may induce a chronic inflammatory milieu
through implant-host interactions that result from constant mechanical shear forces on the
surrounding breast parenchyma.21 Other potential avenues of pathogenesis include
lipopolysaccharide-induced carcinogenesis resulting from higher loads of bacteria found
in subclinical biofilms relative to smooth surface devices,12 as well as aberrant genetic
changes (e.g., JAK-STAT, TP53) as a result of an over-activated immune system.11
In theory, the solution should be as simple as discounting further use of all
textured breast devices; however, it is much more complex. Many authors cite decreased
local complications and adverse outcomes, including lower rates of capsular contracture,
implant malposition, and re-operation that favor the selection of textured devices over
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smooth.6 Therefore, textured breast devices remain attractive in many countries
throughout the world, including the U.S. and recent evidence has suggested that their use
is increasing.96
In 2019, the U.S. Food and Drug Administration (FDA) conducted hearings on
breast implant safety, ultimately concluding that the evidence to ban textured devices was
insufficient.113 Nevertheless, governmental regulatory bodies, including FDA, continue to
debate the scientific validity of an exclusive association between textured surface breast
implants and BIA-ALCL, citing a lack of evidence as well as reports documenting a
history of smooth devices. The culmination of BIA-ALCL, along with other issues
surrounding breast implants (e.g., breast implant illness),35,114 led the FDA to mandate
black box warnings on all breast implants, regardless of filling (saline vs. silicone) or
surface (textured vs. smooth).10 The proposed warnings are outlined in Table 5-1. As
such, there is an immediate need to determine the oncologic safety of both smooth
surface and textured breast devices using high-quality epidemiological studies.
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Table 5-1. U.S. Food and Drug Administration Proposed Warnings for Breast
Implants
Description
Breast implants are not considered lifetime devices. The longer people have them, the
greater the chances are that they will develop complications, some of which will require
more surgery
Breast implants have been associated with the development of a cancer of the immune
system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
This cancer occurs more commonly in patients with textured breast implants than smooth
implants, although rates are not well defined. Some patients have died from BIA-ALCL
Patients receiving breast implants have reported a variety of systemic symptoms such as
joint paint, muscle aches, confusion, chronic fatigue, autoimmune diseases and others.
Individual patient risk for developing these symptoms has not been well established.
Some patients report complete resolution of symptoms when the implants are removed
without replacement
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Cancer epidemiology plays an essential role in identifying and quantifying risk
factors of a disease in order to guide the development of effective prevention strategies.
Previous epidemiological studies have attempted to quantify the risk of BIA-ALCL
accurately;3–5,7 however, comparisons of published studies are difficult due to a lack of
well-defined study populations and widespread variations in the reporting of
epidemiological parameters. The purpose of this study is to better define the risk of BIAALCL by systematically reviewing the epidemiological literature on the disease.
Determining an accurate risk estimate for commercially available devices is essential for
both patients and providers when considering the risks and benefits of using a textured
breast device. This study also aims to definitively establish an exclusive association
between textured-surface breast implants and foreign-body carcinogenesis that is BIAALCL while simultaneously demonstrating the oncologic safety of smooth devices.
Herein, we report the global epidemiology of BIA-ALCL with a focus on the U.S. breast
implant population while simultaneously assessing the possible association with smoothsurface devices.

Methods
5.1.1

Search strategy
A systematic review of epidemiological population-based cohort studies on BIA-

ALCL was conducted in PubMed, Google Scholar, and EMBASE databases between
March 9-20, 2020 using a combination of BIA-ALCL and epidemiological-related search
terms. Search parameters included the terms and Medical Subject Headings (MeSH)
breast implant-associated anaplastic large cell lymphoma, breast implant(s), lymphoma,
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epidemiology, cancer epidemiology, incidence, and cancer incidence. A search of the
grey literature was also performed. Two independent reviewers screened titles, abstracts,
and full texts of identified articles (RCD, MWC). Disagreement between reviewers was
resolved via discussion until there was 100% agreement. Citation chaining was
performed using Web of Science. Critical appraisal of the evidence was conducted using
a modified STrengthening Reporting of OBservational studies in Epidemiology
(STROBE) checklist that was developed within the aims of the present study. The
modified checklist was comprised of key quality factors including a risk-of-bias
assessment and consisted of 10 total items. A single-point system was used to score each
item. Quality scores were calculated for each article and taken out of 10 (max score) in
order to facilitate comparisons of the relative quality of each study. Higher scores were
indicative of higher overall quality, while lower scores did not necessarily reflect poor
study quality, but rather a lower relative quality assessment compared to other included
studies. Global regulatory agency data were reviewed for epidemiological data related to
BIA-ALCL that were not captured in the main search.
5.1.2

Inclusion and exclusion criteria
Inclusion was limited to primary epidemiological research on BIA-ALCL

reported in prospective cohort studies, case-series, case-control studies, conference
proceedings, and abstracts. Articles comparing the risk of BIA-ALCL to other
lymphomas115 were excluded, as were articles in which the epidemiology of a previously
described cohort had been recently published.7,116 Only articles in the English language
were reviewed. This systematic review was conducted in accordance with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
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5.1.3

Data abstraction and quality assessment
Abstracted data included author, journal, year of publication, country, study

period, number of incident cases, study design, study period, patient-specific cumulative
incidence, implant-specific cumulative incidence, incidence rate (per 100 000 personyears). In cases where the incidence rate was reported differently (e.g., per 1000 personyears), rates were standardized per 100 000 person-years, which is the conventional
method for reporting cancer incidence rates.117 Analytical and descriptive epidemiology
was used to estimate the cumulative incidence (i.e., risk) of BIA-ALCL according to
patient and implant specificity. Cumulative incidence was reported at implant and
patient-specific levels. Levels of evidence were ranked from highest to lowest according
to the American Society of Plastic Surgeons evidence-based rating scales for
prognostic/risk studies (Table 5-2). Regulatory agency-specific epidemiologic data were
collected from Australia, Canada, the Netherlands, the U.S., and the U.K.
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Table 5-2. American Society of Plastic Surgeons Evidence Rating
Scale for Prognostic/Risk Studies
Level of
Evidence
I

II

III
IV
V

Description
High-quality, multi-centered or single-centered,
prospective cohort or comparative study with adequate
power; or a systematic review of these studies
Lesser-quality prospective cohort or comparative
study; retrospective cohort or comparative study;
untreated controls from a randomized controlled trial;
or a systematic review of these studies
Case-control study; or systematic review of these
studies
Case series with pre/post test; or only post test
Expert opinion developed via consensus process; case
report or clinical example; or evidence based on
physiology, bench research or “first principles”
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To investigate the possible association between smooth surface devices and BIAALCL, the FDA’s Manufacturer User Facility Device Experience database, and the
American Society of Plastic Surgeons (ASPS) Patient Registry and Outcomes For breast
Implants and anaplastic large cell lymphoma (ALCL) etiology and Epidemiology
(PROFILE) registry were queried for reports of BIA-ALCL. MAUDE collects medical
device reports on data related to suspected device-associated deaths, serious injuries, and
malfunctions, and the limitations of MAUDE with regard to breast implant safety and
BIA-ALCL have been previously described.39,118 PROFILE is a prospectively maintained
database that collects data regarding breast implants and ALCL.

Results
An overview of the search is shown in Figure 5-1. The initial search generated 81
articles. One additional article was identified in a conference proceeding. Titles and
abstracts from 12 articles were further reviewed to assess for study eligibility. The full
text from nine articles were reviewed. After meeting study inclusion criteria, eight
articles underwent quality assessment and data abstraction (Table 5-3). Disease incidence
was reported in seven studies while incidence rates were described in two studies.
Included studies differed in two main ways: study design and the reporting of incidence
and incidence rates.
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Figure 5-1. PRISMA flow diagram
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Table 5-3. Epidemiological Studies of BIA-ALCL
Author

Year

Country

Study design

Study
period

Largent et al

2011

USA

Retrospective

19942007

Level of
evidence

Incident
BIAALCL
cases

Sample size

Patient
specific
incidence

Implant
specific
incidence

Incidence
rate
(personyears)

II

3

NR

1.46 per
100,000
personyears

NR

1.46 per
100,000

95

(Allergan)
McGuire et
al

2016

USA

Prospective
Cohort

-2014

II

4 initially
(now 8)

17,656

1:2,207
(Allergan)

NR

NR

Cordeiro et
al

2020

USA

Retrospective
Cohort

19922019

III

10

3456

1/355

1/602

NR

Nelson et al

2020

Retrospective
Cohort

19912017

III

USA

(Allergan)

11

9373

1:559 (1.79
per 1000)

1:871
(1.15 per
1000)
(Allergan)

NR

De Boer et al

2018

Netherlands

Retrospective
Cohort

19902016

III

43

3000

1:6920 at
75 years of
age

NR

NR

2.8 per
100,000

NR

NR

NR

1:1947
(Silimed)

NR

(reported as
NNH)
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Campanale
et al

2018

Italy

Retrospective
Cohort

20152017

III

22

LochWilkinson et
al

2019

Australia

Retrospective

20152019

III
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Doren et al

2018

10,000,000

1:36,730
(Mentor
Siltex)
USA

Case Series

19962015

IV

100

3,000,000

NR

1:8500
(Allergan)

1:50,000
(Mentor)

2.03 per
1,000,000
1.86 per
1,000,000
(Allergan)
0.33 per
1,000,000
(Mentor)

5.1.4

U.S. epidemiology of BIA-ALCL

5.1.4.1 Patient-specific risk
Two studies have examined the incidence of BIA-ALCL within the U.S. breast
implant population. Both studies are exclusive to the reconstructive cohort, which
introduces selection bias. The patient-specific cumulative risk within the U.S. ranges
from 1.79 per 1000 (1:559)119 to 2.82 per 1000 (1:355)4 patients with a textured surface
implant. This translates to an overall cumulative risk estimate for patients in the U.S. of
0.003% to 0.29% at 20 years and 26 years, respectively. When considering the
cumulative risk from the time of implantation, proportions ranged from 0.00 at 5 years,
0.002 at 10 years, 0.007 at 15 years, and 0.011 at 20 years,4 while other estimates suggest
a cumulative risk estimate of 4.4 per 1000 patients at 10-12 years and 9.4 per 1000
patients at 14-16 years.119
5.1.4.2 Implant-specific risk
Using analytical and descriptive epidemiology and the data provided in Doren et
al.,3 we calculated manufacturer specific risks in the U.S. breast implant population. U.S.
implant-specific risks are less heterogeneous than global risk estimates with incidences
ranging from 1:602-871 to 1:8500 textured implants, which are exclusive to Allergan
(Dublin, Ireland) textured devices.3,4,101 The risk estimate for Mentor (Mentor Worldwide
LLC, Irvine, Calif.) Siltex implants is 1:51 000. Implant-specific risks for other currently
available textured devices (e.g., Sientra, Santa Barbara, Calif.) in the U.S. market are not
reported.
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5.1.4.3 Incidence rate
U.S. specific incidence rates vary from 0.311 cases per 1000 person-years (95%
CI: 0.118-0.503)4 to 1.46 per 100 000 person-years (95% CI: 0.30-0.43)120 to 2.03 cases
per 1 million person-years [1.86 per million (Allergan); 0.33 per million (Mentor)].3
Following conversion, the standardized incidence rate determined by the present study
of BIA-ALCL in the U.S. ranges from 0.203 per 100 000 person-years to 31.1 per 100
000 person-years, indicating that the cumulative risk of BIA-ALCL is higher than
previously thought. When considering incidence rates according to U.S. manufacturer
specificity, a 5.67-fold difference for Allergan Biocell (1.87per 1 million person-years)
compared to Mentor Siltex (0.33 per 1 million person-years) implants was reported
(p<0.001).3 The incidence rate for Sientra implants was not reported.
5.1.5

Global epidemiology of BIA-ALCL

5.1.5.1 Patient-specific risk
Global risk estimates of BIA-ALCL, according to international regulatory
agencies, are summarized in Table 5-4. In the Netherlands, the age-adjusted incidence of
BIA-ALCL from a textured device is approximately 1:6920 patients with a textured
implant at 75 years of age.121 The Australian Therapeutic Goods Administration
previously reported a risk estimate of 1:1000-1:10 000 patients; however, the risk has
widened to 1:2500 to 1:25 000 patients with a textured breast implant.45 The Italianspecific incidence is 2.8 per 100 000 patients.122 A global heat map is used to illustrate the
geographic distribution of BIA-ALCL cases worldwide (Figure 5-2). This distribution is
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reinforced by showing the breakdown of country-specific cases and related deaths in
Table 5-5.
Table 5-4. Summary of Global Regulatory Agency Risk Estimates of BIA-ALCL
Country
Australia
Canada

United Kingdom
United States

Source
Australian Therapeutic Good
Administration
Health Canada

Medicines and Healthcare
Products Regulatory Agency
Food and Drug Administration
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Risk
1:2500-1:25 000 patients
Overall: 1:24 177
1:3565 (Allergan)
1:16 703 (Mentor)
1:24 000 (implants)
1:3817-1:30 000

Figure 5-2. Geographic distribution of BIA-ALCL cases worldwide
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Table 5-5. Global Distribution of BIA-ALCL
Cases and Attributed Deaths
Country
Cases
Deaths
Argentina
13
1
Australia
112
4
Belgium
12
Brazil
19
1
Bulgaria
1
Canada
34
1
Chile
2
China
1
Colombia
17
1
Czech Republic
1
Denmark
9
Egypt
1
Finland
11
France
58
3
Germany
24
Ireland
1
Israel
8
Italy
50
1
Japan
1
Mexico
7
Netherlands
60
1
New Zealand
16
1
Norway
3
Romania
1
Russia
2
Singapore
1
South Africa
2
South Korea
2
Spain
35
Sweden
8
2
Thailand
1
Venezuela
2
United Kingdom
61
1
United States
307
7
Total
885
34
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5.1.5.2 Implant-specific risk
Manufacture-specific implant risks are outlined in Table 5-6. In Australia, the
current implant-specific risk of BIA-ALCL varies widely, ranging from 1:2832 – 1:86
029 implants.7,102 When considering risk according to manufacturer specificity, the
highest risk was in Silimed polyurethane implant (1:2832 95% CI: 1582-5673), followed
by Allergan Biocell (1:3345 95% CI: 2475-4642) and finally Mentor Siltex (1:86 029
95% CI: 15 440-1 301 759) implants. Health Canada, the Canadian equivalent of the U.S.
FDA, currently estimates an overall risk of 1:24 177 implants.123 This distills down to a
manufacturer-specific risk of 1:3565 (Allergan Biocell) and 1:16 703 (Mentor Siltex) in
the Canadian breast implant population, which translates to a 16.52 increased risk of
Biocell implants. In the United Kingdom, the risk of BIA-ALCL is 1:24 000 implants
inserted.124
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Table 5-6. Manufacturer-specific Global Risk Estimates of BIA-ALCL
Manufacturer
Textured implant
Texturization method
Global risk
type
Allergan
Biocell
Salt loss
1:602 to 1:8500
Mentor
Siltex
Negative imprint
1:6703-1:86
029
Sientra
Proprietary method
1:200 000*
Silimed
Polyurethane
Foam-coated
1:2832
*Non-epidemiologic

study by Calobrace et al.
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5.1.6

BIA-ALCL is exclusively associated with textured-surface breast implants
U.S. and non-U.S. population-based, and case-control studies, in combination

with a review of government databases, consistently revealed an association between
textured-surface breast implants and the incidence of BIA-ALCL. Importantly, not a
single epidemiological study or government database reported a case of BIA-ALCL
occurring solely in the context of a smooth surface breast implant.

Discussion
This systematic review provides a detailed examination of existing epidemiologic
data on the global risk of BIA-ALCL. In lieu of a conventional systematic review based
on randomized clinical trials, this comprehensive review is comprised of epidemiological
observational studies of BIA-ALCL in the breast implant population. The heterogeneity
of reported data precluded meta-analysis and limited the calculation of combined risk
estimates. Irrespective of this, we were able to draw comparisons between studies by
standardizing epidemiological parameters whenever possible.
As demonstrated, the risk of BIA-ALCL varies substantially, especially when
considering incidence according to manufacturer type. In the U.S. market, the average
lifetime risk of BIA-ALCL ranges from 1:355 – 1:51 000 patients with a textured surface
breast implant. Allergan’s Biocell implants carry that highest manufacturer-specific risk
at 1:2207-1:8500,3,101 followed by Mentor Siltex implants at 1:51 000. This translates into
a nearly six-fold increase in the risk of BIA-ALCL when comparing Allergan Biocell to
Mentor Siltex breast implants (p<0.001). These data, among others, weighed heavily on
the decision for the U.S. FDA to issue a Class 1 recall, the most serious type of recall, on
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all Allergan textured breast devices. With the removal of Allergan textured devices from
the U.S. and other markets worldwide, much of the currently available epidemiologic
data does little to mitigate risks for patients currently considering the use of a textured
breast device for breast reconstruction or cosmetic augmentation. As such, there is a
paucity of epidemiological data for commercially available textured breast implants
which is highly concerning from a patient safety perspective.
As shown in the present study, the increased risk of BIA-ALCL associated with
Allergan textured breast implants in the U.S. is well-established. Conversely, risk
estimates for Mentor products (1:51 000) are less well-established, and the risk of Sientra
implants has gone virtually unreported in the U.S. literature. A single non-epidemiologic
U.S. based study reported a combined 20-year, worldwide risk of BIA-ALCL for Sientra
and Silimed (Rio de Janeiro, Brazil) of 1:200 000 implants.6 Therefore, based on the
findings of the present study, the current risk of BIA-ALCL for commercially available
devices likely resides somewhere between 1:51 000-1:200 000. However, it is unclear
how the upper limit of that risk estimate stratifies according to manufacturer type or if it
is generalizable to the U.S. population given the methodologies used to arrive at that
calculation. Combined with the removal of Allergan devices from the U.S market, these
data, along with a limited number of other risk estimates, do little to guide implant
selection for patients considering breast augmentation or breast reconstruction with a
textured surface device. Future risk assessment studies on currently available breast
devices are warranted.
The present study also identified clustering of cases in the U.S., Australia and
New Zealand, the U.K., the Netherlands, and France, with widespread geographic
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variation in global risk estimates. The highest number of cases occurred in the U.S.,
which accounts for 1 out of every 2.6 cases (38.4%) worldwide. These data coincide with
recent risk estimates suggesting the highest incidence of BIA-ALCL within the U.S.
breast implant population. These data are somewhat surprising, given that textured breast
devices account for less than 10% of sales in the U.S. market.6 Conversely, Australia is
predominantly a textured device market, yet it only accounts for 1:7 cases (14.3%). These
differences in clustering and subsequent risk profiles are likely a result of increased
awareness, improved surveillance, access to care, and long-term follow-up, rather than
epidemiologic or pathologic phenomena. Unfortunately, there is a misconception held by
few that clustering of BIA-ALCL cases is indicative of poor breast implant technique.
Given that no evidence currently exists to support an association between surgical
technique and BIA-ALCL tumorigenesis, the authors of the current study vehemently
oppose such a notion that threatens to undermine the reporting of future cases amongst
surgeons. Previous studies have also suggested that genetics may account for differences
in worldwide incidence, citing the lack of clustering in the Asian breast implant
population as evidence.6,22,102 This concept has recently been challenged with reports of
BIA-ALCL emerging in this population.125 While genetics, more specifically epigenetics,
may account for geographic variations in cumulative risk found in the present study, the
current evidence does not support such a concept at this time.
Texturization plays a critical role in the malignant transformation of BIA-ALCL.
Yet, regulatory agencies remain reluctant to acquit smooth surface devices. Importantly,
we did not find a single case of BIA-ALCL that had been reported to PROFILE where a
patient had a pure history of a smooth implant. As of July 2019, FDA’s MAUDE
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database acknowledged 457 unique medical device reports with a BIA-ALCL diagnosis,
of which 26 are recognized as occurring with a smooth device.126 Of those, 12 have an
unknown prior implant history, 7 have a history of a prior textured implant, and in 7
cases, surface characteristics were unknown. Contradicting these reports, this systematic
review found no published reports of the disease occurring exclusively with a smoothsurface device. Moreover, this study failed to identify a single case of BIA-ALCL
associated with a smooth device in any registry or government database where a patient
had not already been exposed to a textured device, which includes exposure to a textured
tissue expander. FDA currently denies any association between textured expanders and
BIA-ALCL; however, it is important to note that PROFILE does recognize two cases of
ALCL have occurred in patients receiving tissue expander breast reconstruction with a
textured-surface expander followed by permanent implant exchange with smooth surface
implants.112 While the sample size is small, this reinforces the concept of texturization
and the role it plays in malignant transformation.
5.1.7

Limitations
The current study is only as strong as the quality of data that were abstracted

during the search. Retrospective designs have limited previous epidemiological studies of
BIA-ALC, along with extrapolated denominators based on inaccurate implant sales
figures, incomplete clinical data, and a lack of long-term follow-up, all of may act as
potential sources of bias in the present study. This systematic review also limited
inclusion criteria to articles exclusively disseminated in the English language. As such, it
is possible, although highly improbable, that epidemiological studies on BIA-ALCL may
exist in other languages. Additionally, the lack of reported cases of BIA-ALCL with
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smooth devices precluded a calculation of the relative risk of smooth vs. textured devices.
Finally, differing methodologies combined with the heterogeneity of data, we were
unable to standardize all epidemiological parameters across studies or assess temporal
trends in the risk of the disease.

Conclusions
This is the first systematic review on the epidemiology of BIA-ALCL in the
breast implant population. Of great concern, this systematic review identified substantial
gaps in the epidemiological knowledge of BIA-ALCL that have resulted from a dearth of
high-quality epidemiological evidence and widespread differences in reporting which
hinder the interpretation and generalization of risk estimates. These differences highlight
the importance of standardized reporting of age-adjusted epidemiological parameters to
allow for more reliable comparisons across various breast implant populations.
Specifically, the present study demonstrated significant global geographic and
manufacturer-specific variation in the risk of the disease. Further investigation of
demographic, epigenetic, and environmental risk factors, including implant surface
characteristics, may account for these differences and is therefore warranted. With the
removal of Allergan textured devices, this study also found that the current risk of
commercially available textured-surface breast implants, specifically in the U.S. market,
is not well-defined and impairs the ability to provide a thorough informed consent
thereby threatening patient safety. Patients and providers should exercise extreme caution
when considering the use of a textured breast device for cosmetic or reconstructive
purposes. Finally, this systematic review demonstrated that there is no evidence to
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support the hypothesis that BIA-ALCL is associated with smooth-surface breast implants
at this time. Although these data suggest that smooth-surface breast implants are
oncologically safe, more extensive prospective studies are needed before definitive
conclusions may be drawn.

109

CHAPTER 6. ABERRANT JAK-STAT3 SIGNALING IS A KEY MOLECULAR
FEATURE OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL
LYMPHOMA
Abstract
Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is
an emerging lymphoma linked to textured-surface breast implants. The molecular
mechanisms responsible for lymphomagenesis remain poorly understood. This study
utilizes transcriptional profiling to mechanistically investigate the molecular pathogenesis
of BIA-ALCL. Methods: Purified RNA isolates from BIA-ALCL and benign breast
implant capsule specimens underwent hybridization-based transcriptional profiling using
a 770-gene panel (Nanostring) comprising 13 known cancer pathways. Global
significance scoring of differential expression profiles was used to identify pathways of
interest and guide gene selection. Genes of interest were further selected based on
statistical significance (p < 0.05) with a Benjamini-Yekutieli correction to control the
false discovery rate. Immunohistochemistry was used to validate gene expression.
Results: BIA-ALCL tumors showed a 2.26-fold upregulation of STAT3 gene expression
(p < 0 .014) as well as upregulation of other JAK-STAT3 pathway genes relative to
controls. Global significance scoring revealed highest pathway activation in BIA-ALCL
occurring in JAK-STAT. Furthermore, pathways involved in apoptosis avoidance and
cell-cycle progression were differentially upregulated compared to pathways involved in
cell growth and differentiation that were downregulated. Immunohistochemistry revealed
BIA-ALCL samples had a significantly higher average of pSTAT3+ cells per high power
field (68.65±31.57) than benign capsular tissues (23.93±16.93; p < 0.031). Conclusion:
BIA-ALCL tumors employ pervasive JAK-STAT pathway activation. Involvement of
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JAK-STAT represents an attractive area for therapeutic intervention in patients with
advanced-stage disease and provides avenues for future investigation that might lead to
an increased understanding of the mechanisms of lymphomagenesis in BIA-ALCL and
potentially other types of ALK- ALCL.

Background
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an
emerging type of T-cell lymphoma that can form around saline or silicone-filled texturedsurface breast implants.37,40,41,79 These tumors uniformly and strongly express CD30, are
negative for anaplastic lymphoma kinase (ALK) and carry clonal T-cell receptor gene
rearrangements. Since the index case of this disease, which was first reported in the mid
to late 1990s,2,91,92 over 800 cases have been reported worldwide.42 The average lifetime
risk ranges from 1:355 – 1:30,000 persons with a textured-surface breast implant, but can
vary significantly when stratifying risk according to manufacturer type.4,7,102 In general,
BIA-ALCL cases typically present as an acute-onset periprosthetic fluid collection
occurring at least one year after device implantation. 27,40 Although most cases typically
follow an indolent clinical course when diagnosed and treated promptly, gaps in the
understanding of disease development and progression have limited early diagnosis and
treatment—leading to poor clinical outcomes including metastatic disease and death in a
subset of patients.30,31,109 The present study remains one of the first clinical research
studies utilizing BIA-ALCL patient samples to better discern the factors contributing to
the development of this disease.
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The central obstacle to advancing BIA-ALCL therapies for patients presenting
with aggressive disease remains the overall lack of understanding of molecular drivers of
this malignancy. Clinicians and scientists have developed multiple viable hypotheses
regarding disease etiology, including pathogen-mediated oncogenesis occurring from
lipopolysaccharide-induced tumorigenesis,12,87 oncogenic viruses,17 chronic trauma to the
breast pocket leading to malignant transformation,21 chemical structures from the
textured device that facilitate aryl hydrocarbon receptor-mediated T-cell proliferation22
and allergen-driven chronic inflammation.63,64 Despite this wide swath of proposed
theories, all of the factors mentioned above point toward the development of a chronic
inflammatory state within the breast pocket that ultimately results in an unregulated Tcell clonal expansion.20,46 After almost two decades of continued investigation, the
scientific data supporting the exact mechanisms driving BIA-ALCL tumorigenesis and
progression remain largely underdeveloped.1 Demanding growth requirements for BIAALCL tumor cell lines (TLBR 1-4) and the lack of a validated animal model19 have
further impeded scientific progress, but of more pressing concern remains the deficiency
in well-designed primary research studies utilizing patient tissue samples for scientific
discovery; the present study hopes to address this need.
Overwhelming evidence implicates aberrant JAK-STAT activation in almost
every type of T-cell specific malignancy—ranging from T-cells transformed by human Tcell lymphotrophic virus 1 (HTLV-1), acute lymphoblastic leukemia (ALL) and
including ALK+ and ALK- anaplastic large cell lymphoma.56,127,128 In ALK- ALCL, like
BIA-ALCL, anywhere from 47-80% of known genetic mutations occur within the JAKSTAT pathway, leading to increased STAT3 Y705 phosphorylation and nuclear

112

localization.56 Despite these findings, only one study has investigated the transcriptional
profile of BIA-ALCL.17
The current study aims to conduct transcriptional profiling of BIA-ALCL tumor
specimens compared to benign breast implant capsules to better understand the molecular
pathogenesis of BIA-ALCL. It is hoped these insights will better inform the diagnosis
and treatment of this emerging disease. Inquiry into this specific molecular activating
pathway is likely to yield clinically useful results, as specific JAK inhibitors have shown
promise in blocking both cytokine-receptor activation and receptor-phosphorylation
events in other T-cell malignancies. We hypothesize that BIA-ALCL samples, like other
ALK- ALCLs, will harbor genetic mutations within the JAK-STAT pathway representing
aberrant signaling activation that directly leads to increased nuclear localization of
pSTAT3 within affected tissues.

Materials and Methods
6.1.1

Ethics statement
A pilot case (BIA-ALCL)-control (benign breast implant capsules) study was

conducted to investigate the molecular profiles of BIA-ALCL. Tumor samples were
collected under a protocol approved by The University of Texas MD Anderson Cancer
Center institutional review board (IRB) protocol, and healthy tissue samples were
collected under an approved IRB protocol at the University of Kentucky Markey Cancer
Center.
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6.1.2

Patients and samples
After obtaining informed consent, BIA-ALCL tumor specimens (n = 4) were

collected from adults undergoing oncologic resection at The University of Texas MD
Anderson Cancer Center. Two independent pathologists from the Department of
Hematopathology confirmed the diagnoses. Investigators obtained informed consent from
each patient, and samples were coded before analysis. Healthy control tissue (n = 8)
consisted of breast implant capsules obtained during breast implant exchange or from
patients undergoing tissue expander to permanent implant exchange. All specimens were
fixed in 10% neutral-buffered formalin overnight and embedded in paraffin (FFPE) for
future use. Clinicopathologic data, including age at diagnosis or implant removal, the
median time from initial implantation to presentation, tumor stage (where applicable),
and implant surface characteristics (smooth vs. textured) were collected for both cohorts.
6.1.3

RNA extraction and transcriptional profiling
Messenger RNA (mRNA) was extracted from tumor (n = 4) and healthy control

(n = 8) FFPE specimens per the manufacturer’s protocol using a QIAGEN Allprep
DNA/RNA Mini Prep Kit (Hilden, Germany). mRNA was stored at -80°C. mRNA
quality was determined by visualization of 18S and 28S bands using the Agilent 2100
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA). Three BIA-ALCL tumor
specimens (ALCL 3 excluded) and eight healthy breast implant capsule specimens met
RNA quality thresholds and were utilized for quantitative analysis. Next, mRNA was
subjected to the Nanostring nCounter Sprint Profiler system (Nanostring Technologies,
Seattle, WA) using the Pancancer Pathways Codeset for human tissue. Nanostring uses
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multiplex hybridization technology with a panel of over 770 cancer-associated human
genes, representing 13 canonical cancer-associated pathways as well as six housekeeping
genes.129 Raw counts were generated using the human PanCancer pathways panel and
normalized using endogenous controls. Directed global significance scoring (GSS) was
used to identify pathways of interest and guide gene selection. Genes of interest were
further selected based on statistical significance (p < 0.05).
6.1.4

Immunohistochemistry
Tissues were fixed in 4% neutral buffered formalin overnight, processed through

paraffin, and sectioned at 5μm before analysis as above. Samples were stained with
pSTAT3Y705 (Cell Signaling, Danvers, MA). Briefly, paraffin sections were serially
hydrated through graded alcohols before antigen retrieval with citrate buffer (pH 6.0) in a
decloaking chamber (Biocare Medical, Concord, CA). Sections were then incubated in
primary antibody (1:250) overnight at 4°C, washed briefly in buffer before secondary
antibody incubation with an anti-rabbit peroxidase-labeled polymer (Dako, Carpinteria,
CA). Treated sections were then developed using a 3,3’-diaminobenzidine
tetrahydrochloride chromagen (Dako) and counterstained with hematoxylin before
imaging. Additional sections were subjected to Hematoxylin and Eosin (H&E) staining.
6.1.5

Assessment of pSTAT3 Activation
pSTAT3 activation was defined as nuclear positivity of pSTAT3 antibody within

the tissue sample prepared as detailed above. Four independent ALCL and four
independent benign capsule tissues were analyzed initially at low power magnification
and representative images—where sufficient cellular positivity with minimal background
115

was evident—were obtained at high power (400X) magnification. At least ten
representative images were obtained per sample. From these representative images,
between 5-10 high power fields (HPF) for each sample were used for scoring. All images
were processed using Image J software (National Institutes of Health, Bethesda, MD),
and positive cells were marked using program tools to improve precision. Scoring criteria
consisted of counting positive cells per HPF in a blinded fashion. Two investigators
participated in the scoring (RCD, EBL) and submitted their counts independently for
statistical analysis.
6.1.6

Statistical analysis
Gene expression analyses were conducted using the Nanostring nSolver (Version

4.0) and Nanostring nCounter Advanced Analysis software (Version 2.0.115). A
Benjamini-Yekutieli correction was used to control the false discovery rate. An unpaired
Student’s t-test with Welch correction was used to assess pSTAT3 cell counts. All nongene expression analyses were conducted using GraphPad Prism (Version 8.2.1, San
Diego, CA). Clinicopathologic characteristics were described using descriptive statistics.
Alpha was set at p < 0.05 a priori.

Results
6.1.7

Clinicopathologic characteristics
Clinicopathologic characteristics, therapies, and outcomes are described in Table

6-1. The median age of patients diagnosed with BIA-ALCL was 58.5 years (range: 41-76
years). All patients (100%) were exposed to an Allergan Biocell textured-surface breast
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implant. The median interval time to diagnosis following implantation was 9.0 years
(range: 6-13 years). Twenty-five percent of patients had TNM Stage IA, while the
remainder of patients presented as Stage IIA (50%) and Stage IB (25%). Half of patients
(50%) received combination therapy while the other 50% received oncologic resection
exclusively. The median follow-up was 51.5 months (range: 38-140 months). All patients
(100%) achieved complete resolution at long-term follow-up. For the controls (data not
shown), all patients (100%) had a surgical indication of breast reconstruction and were
exposed to an Allergan textured-surface tissue expander.
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Table 6-1. Clinicopathologic features, therapy, and outcomes of patients with breast
implant-associated anaplastic large cell lymphoma (n = 4)
Variable
Patient age
(years)
Surgical
indication
Clinical
presentation
Therapy
Implant surface
Interval time to
diagnosis (years)
TNM stage at
presentation
Follow up
(months)
Clinical outcome

ALCL 1
54

ALCL 2
63

ALCL 3
76

ALCL 4
41

Cosmetic

Reconstruction

Reconstruction

Cosmetic

Effusion

Effusion

Effusion

Mass

CCaps,CHOP,Rad

CCaps

CCaps

Textured Biocell

Textured Biocell

Textured Biocell

CCaps,CHOP,Ra
d
Textured Biocell

8

13

6

10

IB

IIA

IA

IIA

38

140

55

48

CR

CR

CR

CR
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6.1.8

JAK-STAT3 signaling is differentially upregulated in BIA-ALCL tumors
In order to determine which pathway(s) plays a predominant role in BIA-ALCL

tumorigenesis, a panel of 13 canonical cancer pathways was selected to perform
hybridization-based transcriptional profiling using the Nanostring nCounter Sprint
system. Overall, unadjusted differential expression of the 40 most statistically significant
gene transcripts is shown in Figure 6-1. After adjusting p-values to control the false
discovery rate, 44 statistically significant differences in gene expression were identified
between BIA-ALCL samples and benign capsule tissue. (Figure 6-2). Twenty-eight were
found to be upregulated in BIA-ALCL samples, whereas 16 genes were down-regulated
compared to benign capsules. The resulting heat map shows strong hierarchal clustering
of BIA-ALCL tumor specimens, indicating a relatively homogenous molecular
expression profile among these tumors. Using pathway scoring and directed GSS,130 we
identified pathways with the highest upregulation (Figure 6-3). Areas of high scoring
included pathways related to chromatin modification, DNA damage and repair, cell cycle
progression and apoptosis, transcriptional dysregulation, oncogenic driver genes, and the
JAK-STAT3 pathway. According to GSS, BIA-ALCL samples showed the highest
activation of JAK-STAT3, indicating aberrant expression of the pathway. STAT3
expression specifically exhibited a 2.26-fold-change in BIA-ALCL tumors (p < 0.013)
(Figure 6-4). A KEGG signaling pathway demonstrating downstream events in aberrant
JAK-STAT signaling in BIA-ALCL is shown in Figure 6-5. The KEGG pathway
highlights the important role that aberrant JAK-STAT3 pathway activation plays in
driving 12 other canonical cancer pathways (Figure 6-6).
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Figure 6-1. Volcano plot of differential gene expression in BIA-ALCL compared to
benign breast implant capsules.
Horizontal lines represent various false discovery rate thresholds.
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Figure 6-2. Heatmap of differential gene expression in BIA-ALCL vs. healthy controls.
Note the hierarchal clustering of tumor specimens (BIA-ALCL) and healthy control
tissue (benign breast implant capsules). Red denotes increase gene expression while
green signifies decreased gene expression.
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Figure 6-3. A) Heatmap of pathway scores. B) Directed global significance scores.

Figure 6-4. A) Volcano plot of differential gene expression for the JAK-STAT3
pathway. B) Relative mRNA expression of STAT3.
Horizontal lines denote various false discovery rate thresholds. *p < 0.05.
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Figure 6-5. JAK-STAT signaling pathway.
Overview of KEGG pathway diagram of differentially expressed JAK-STAT3 signaling
pathway genes in BIA-ALCL. Orange denotes increased expression while blue signifies
decreased expression.
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Figure 6-6. KEGG pathway showing global gene expression and interaction between
13 cancer-associated pathways in BIA-ALCL.
Orange indicates increased gene expression and blue indicates decreased gene
expression.
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6.1.9

pSTAT3 is aberrantly activated in BIA-ALCL
Work in other types of ALK- ALCL has shown that activating mutations in the

JAK-STAT pathway leads to increased nuclear localization of pSTAT3Y705;56 however,
this has not been investigated in BIA-ALCL. Having established significant genetic
alterations in JAK-STAT pathway contributors in BIA-ALCL patient samples in previous
experiments, we set out to determine the activation status of STAT3 at the protein level
using IHC analysis. Representative pSTAT3 images with paired H&E images are shown
in Figure 6-7A. Cell counts performed on 5-10 high-magnification images per sample
revealed that BIA-ALCL samples had a significantly higher average of pSTAT3+ cells
per HPF (68.65±31.57) than benign capsular tissues (23.93±16.93; p < 0.031) (Figure 67B).
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Figure 6-7. pSTAT3 Signaling in BIA-ALCL samples.
A) H&E and pSTAT3 immunohistochemical staining performed on benign capsular
tissue and tumor samples isolated from patients with biopsy-proven BIA-ALCL. B)
pSTAT3+ cell counts per HPF performed on independent benign capsules (n = 4) and
BIA-ALCL
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Discussion
Recent work has established BIA-ALCL as a highly treatable specific type of
ALK- ALCL that is associated with textured-surface breast implants.25,30 Early
investigation implicated activating genetic mutations as the central drivers in BIA-ALCL
tumorigenesis and progression. However, the evidence to substantiate these claims was
lacking—specifically regarding the translation of known genetic mutations to oncogenic
pathway activation.131 This current study sought to identify the molecular drivers of BIAALCL using hybridization-based transcriptional profiling to identify actionable genetic
mutations leading to oncogenic pathway activation—aiding in the diagnosis and
treatment of the disease. With the knowledge that other types of ALK- ALCL rely on
aberrant JAK-STAT pathway activation, we hypothesized that BIA-ALCL samples
would harbor genetic mutations within this pathway that would lead to an increase in
nuclear localization of pSTAT3. Consistent with our hypothesis, we found that BIAALCL tumors exhibit widespread JAK-STAT3 pathway upregulation, including a 2.26fold-change in STAT3 expression. Constitutive pathway activation directly correlated
with increased pSTAT3 nuclear localization in BIA-ALCL tissues by IHC, demonstrating
that increased STAT3 gene expression results in protein phosphorylation and downstream
events that stimulate proto-oncogenes (MYC, CCND1, and PIM1).
Data from this study revealed several key characteristics of BIA-ALCL that
underpin a disease pathogenesis that is unique and distinct from other types of
lymphoma. Despite activating mutations in JAK-STAT pathway constituents occurring in
the minority (~20%) of T-cell lymphomas, gain-of-function mutations traditionally lead
to enhanced growth capabilities of affected cells.132 Using Nanostring technology, our
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current study identified a decrease in growth factor (PDGF, FGF2) and growth factorreceptor (PDGFR) related gene expression in BIA-ALCL samples. Further, GSS and
pathway analysis scoring revealed decreased activation in pathways involved in growth
and differentiation, including PI3K, Wnt, and MAPK. Within hematologic malignancies,
overexpression of PI3K or Wnt signaling has been linked to a poorer prognosis 133 and
treatment resistance. BIA-ALCL remains very treatable, albeit through complete surgical
excision, indolent disease process, which may explain the downregulation of PI3K rather
than indicating a functional change in cellular growth capacity or the nutrient availability
within the tumor microenvironment. Tumor cells undergo oncogenesis in multiple
ways—namely through rapid upregulation of growth pathways superseding regulatory
measures that would otherwise limit cellular expansion or through the careful avoidance
of apoptotic and immune clearance protocols for defective or mutated cells.134 GSS and
pathway analysis performed in this study reveal that BIA-ALCL cells most likely avoid
clearance, as the highest scores obtained in this study were in pathways involved in DNA
damage repair, transcriptional dysregulation, and cell cycle control-apoptosis.
Importantly, mutations in the p53 protein family—a strong activator of apoptotic
paradigms—have been linked to BIA-ALCL cases.79 Taken together, the data from this
study support the notion that BIA-ALCL tumor cells have modest cellular growth
activation and achieve lymphomatosis through the alteration of cell-cycle checkpoints
and avoidance of apoptosis paradigms.
Our sequencing data corroborate other BIA-ALCL studies by Blombery et al.,51,52
Di Napoli et al.,53 and Oishi et al.,16 who independently implicated JAK-STAT3 pathway
activation in disease pathogenesis. Importantly, Blombery and colleagues were the first to
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link gain-of-function mutations in STAT3 p.S614R and JAK1 somatic variant (G1097V)
with the disease.52 In a follow-up study, this group identified the first somatic STAT3
mutation conserved between 7 of 11 independent BIA-ALCL samples studied using
targeted-next generation sequencing (NGS), implicating shared JAK-STAT activation in
disease progression. Similarly, Oishi and colleagues interrogated 15 unique BIA-ALCL
tumor specimens by NGS.16 In addition to the known oncogenic variants, this group
identified a STAT3 p.S616R variant, while simultaneously discovering two instances of
novel STAT3 Y640F gain-of-function mutations, as well as a JAK1 missense variant
(G1097D). Both the S616R and Y640F amino acid substitutions affect the SH2 domain,
which is known to activate STAT3 constitutively, suggesting that these gain-of-function
mutations could be definitively linked to nuclear localization of activated protein.
Following up on this idea, Letourneau et al. linked dual activating JAK1 (G1079V),
STAT3 (p.S614R) mutations, and high pSTAT3 expression in a single case of BIAALCL.77 Our study builds on the current literature by providing direct evidence that
activating mutations in the JAK-STAT pathway lead to pSTAT3 nuclear localization.
Specifically, we found a 2.26-fold increase in STAT3 expression in BIA-ALCL tumor
specimens relative to controls (p < 0.014), and these data were strengthened by the 3-fold
increase in nuclear localization of pSTAT3 protein (p < 0.03). Our work suggests that
JAK-STAT activation is pervasive across independent BIA-ALCL samples and is a
distinct feature separating disease tissue from benign capsular controls.
The JAK-STAT pathway has multiple distinct levels of activation, and elevated
pSTAT3 nuclear localization could be an indication of a chronic inflammatory milieu
within the breast pocket rather than a true pathognomonic finding in ALCL. To
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investigate changes within the T-cell population specifically, Di Napoli et al. interrogated
the molecular signatures of microdissected BIA-ALCL tumor specimens (n = 6) as
compared with normal T-cells and other peripheral T-cell lymphomas.17 Gene set
enrichment analyses revealed STAT3 activation when comparing transcripts from BIAALCL tumor specimens to healthy T-cells, suggesting that STAT3-related signaling
mechanisms are inherent to the BIA-ALCL disease process, not necessarily to all T-cell
lymphomas. In line with this thinking, Lechner and colleagues demonstrated that BIAALCL tumor cell lines (TLBR-1) showed increased activation of STAT3 and that
exposure to a STAT3-specific inhibitor resulted in tumor cell death;83 molecular testing of
TLBR 2 - 4 later showed similar results.82 Collectively, these data suggest a possible
avenue of lymphomagenesis that may progress from chronic inflammation to true
oncogenesis through the JAK-STAT3 pathway.11 This theory introduces multiple levels
of potential intervention to ablate JAK-STAT signaling and prevent transformation to
BIA-ALCL or limit the progression of the disease to a higher stage.
Localized BIA-ALCL typically responds to en bloc resection, which includes
removal of the implant with complete capsulectomy and obtaining clear margins.
However, in advanced disease, which can include lymph node involvement or distant
metastasis, per NCCN guidelines, patients should receive adjuvant chemotherapy, or
radiation.32 Currently approved recommendations include CHOP therapy and doseadjusted EPOCH. Nevertheless, ALK- ALCL cases convey 5-year survival rates around
49%, and BIA-ALCL, which exhibits 5-year survival rates around 75%, are more likely
to follow a relapsing-remitting course than patients with ALK+ ALCL.135,136 As such, our
data showing pervasive JAK-STAT activation in BIA-ALCL might inform treatment
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strategies for advanced disease to improve long-term outcomes. Specifically, the presence
of JAK-STAT inhibitors represents an untapped area of potential research for affected
patients. Work by Chen and colleagues revealed that ALK- ALCL cells, in vitro, depend
on JAK1 and STAT3 for survival.88 Further, this group demonstrated that pSTAT3+
ALK- ALCL cells in vitro and in a xenograft model of ALCL were sensitive to JAK
inhibitors, including ruxolitinib. Taken together, with the pervasive JAK-STAT
activation seen in the current study, JAK inhibitors represent an attractive area of future
research in patients with advanced disease refractory to standard adjuvant therapy
recommendations.
6.1.10 Limitations
While this pilot study revealed several key characteristics of BIA-ALCL, some
limitations should be considered when interpreting the results. While statistically
significant differences in gene expression were identified, it is important to note that our
study may have been somewhat limited by statistical power due to the small number of
tumor specimens available to interrogate. While this is an inherent limitation of studying
a rare disease, these gene expression profiles may not be representative of all BIA-ALCL
tumors, particularly when considering differences across pathologic stage. Nevertheless,
the fact that we did achieve statistical significance in our pathway (JAK-STAT) and
genes of interest (e.g., STAT3) demonstrates that the present study was adequately
powered to detect those differences. Transcripts that did not show differential expression
profiles may be a result of limited statistical power that could result in a type II error, or it
may simply be indicative of a lack of gene involvement. Nevertheless, it is possible that
gene expression patterns and downstream effects may show differences in a larger study.
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Conclusions
Oncogenic signaling in BIA-ALCL is highly complex and exhibits widespread
JAK-STAT pathway involvement as well as other cancer-associated pathways.
Differential expression of the JAK-STAT3 pathway may provide a mechanism for
malignant transformation of lymphocytes residing within benign breast implant capsular
tissue. These data provide novel insights into the biological basis of BIA-ALCL and
highlight the potential role of STAT3 as a potential biomarker, as well as providing a
novel therapeutic target. Future work should seek to determine the role of STAT3 as a
diagnostic tool and prognostic indicator and to identify whether or not expression
correlates with disease severity (e.g., TNM staging). Large scale, functional analyses are
needed to determine further the central role genetics may play in BIA-ALCL
tumorigenesis and progression.
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CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
BIA-ALCL is an emerging cancer on the immune system associated with textured
surface breast implants. Although the knowledge of the disease has evolved rapidly in
recent years, specifically regarding diagnosis and treatment, the evidence supporting
current clinical recommendations has not been critically appraised. Widespread variations
in epidemiological reporting have only complicated the ability to mitigate risks
associated with textured devices. Adding to the complexity of the disease, the molecular
mechanisms responsible for BIA-ALCL tumorigenesis have yet to be elucidated. This
chapter provides a brief summary of the findings of this dissertation and establishes
research priorities for current and future research endeavors.
Current evidence aligns with consensus guidelines and treatment recommendations
Recent treatment advances have been highlighted by complete surgical resection
and device removal as the standard of care in the majority of cases. Other advancements
include the reservation of adjuvant therapy for cases with advanced disease or those
refractory to oncologic resection, as well as reconstructive techniques following complete
resolution. Despite the limited number of high-quality studies related to the diagnosis and
treatment of BIA-ALCL, this study demonstrated that current evidence supports clinical
recommendations and aligns with National Comprehensive Cancer Network consensus
guidelines. It also provides a comprehensive clinical update on the epidemiology and
pathophysiology of the disease, in addition to the advances in diagnosis and treatment as
just described. Given the number of women with breast implants who are at risk for
developing the disease, this study reinforced current clinical guidelines while bringing a
134

heightened awareness of this emerging disease to clinicians from diverse specialties
including breast surgeons, surgical oncologists, plastic surgeons, and pathologists, as well
as general practitioners that encounter patients with textured breast implants in their daily
practice.
Smooth surface devices are oncologically safe; the risk of BIA-ALCL is not well
defined
This is the first study to review the epidemiology of BIA-ALCL systematically.
Not surprisingly, this study demonstrated substantial gaps in the current knowledge
regarding risk profiles and BIA-ALCL tumorigenesis for currently available texturedsurface breast devices in the U.S. market. With the removal of Allergan textured surface
devices from the U.S. market, the risk of BIA-ALCL for currently available textured
devices is not well-defined. Given these findings, an accurate risk of BIA-ALCL cannot.
As such, surgeons are strongly advised against utilizing textured devices regardless of
whether it is for cosmetic or reconstructive purposes until more accurate risk profiles can
be determined.
As previously mentioned, certain governmental regulatory agencies (e.g., U.S.
FDA) maintain that there is a possible association between smooth surface devices and
BIA-ALCL. Refuting those claims, this study also illustrated the oncologic safety of
smooth surface devices. Despite this finding, larger prospective studies with head-to-head
comparisons between smooth surface and textured breast devices are needed before
definitive conclusions should be drawn.
JAK-STAT3 pathway upregulation is a key molecular feature of BIA-ALCL tumors
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Previous molecular studies have sought to determine the molecular events
responsible for oncogenic transformation. However, the biologic mechanisms remain
poorly understood. Hybridization-based transcriptional profiling was used to compare
molecular signatures in BIA-ALCL tumors to healthy controls in order to investigate the
molecular mechanisms of the disease. This represents one of the first studies undertaken
that attempts to better understand the pathogenesis of this rare but emerging disease. Of
particular interest was the observation that BIA-ALCL tumors exhibit pervasive JAKSTAT3 upregulation that results in downstream events that promote tumorigenesis
through the alteration of cell-cycle checkpoints and avoidance of apoptosis paradigms.
Based on these findings, a novel mechanism was proposed whereby an over-active
immune system facilitates the malignant transformation of peri-implant lymphocytes via
the JAK-STAT3 pathway. These data highlight the JAK-STAT pathway as a novel
therapeutic target for patients with advanced disease while providing avenues for future
investigation that might lead to an increased understanding of the mechanisms of
lymphomagenesis in BIA-ALCL and potentially other types of ALK- ALCL.
Future directions
In-vivo model of BIA-ALCL
An in vivo model of BIA-ALCL is needed to further elucidate the molecular
mechanisms not only responsible for tumorigenesis but also disease progression. Our
group has previously suggested that CRISPR-Cas9 technology may be used to engineer a
murine model of pathogenesis under a variety of conditions.19 Perhaps more feasible
would be the development of a xenograft model using established tumor cell lines to
further interrogate mechanisms of pathogenesis and to assess the efficacy of targeted
therapies (e.g., “JAKanibs”). Although, the reluctance among investigators to deposit
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tumor cell lines in tumor repositories complicates such an endeavor. As mentioned in this
dissertation, previous cell lines have since been discontinued by ATCC. Another
interesting avenue of research would be the use of an IL-10 knockout in order to further
investigate the role of the chronic inflammation and to assess possible differences that
may exist in how smooth surface and textured devices influence the inflammatory milieu.
Macrophage phenotype and particulate matter digestion
Macrophage phenotype is known to influence the tumor microenvironment.
Specifically, differentiation to an M2 or alternatively activated phenotype exhibits antiinflammatory, pro-tumor effects.137 Further investigation should seek to determine the
predominant macrophage phenotype in BIA-ALCL and if polarization to tumorassociated macrophages plays a role in shaping the tumor microenvironment to promote
progression and metastasis. Conceptually, this could be achieved by using a macrophage
polarization model co-cultured with BIA-ALCL tumor cells. Although this is an
oversimplification of the cellular and molecular events under experimental conditions,
such an investigation may inform future avenues of research that could potentially
reprogram M2 macrophages to an M1 phenotype which could allow for targeted
therapies, possibly alleviating the necessity of complete surgical resection or the need for
adjuvant therapy under certain conditions.
As discussed in chapter three, macrophage digestion of foreign particles, possibly
from the surface of textured devices, may lead to frustrated phagocytosis resulting in a
chronically over-activated immune system that predisposes to errors in DNA replication
and driver gene mutations (e.g., STAT3).
Correlation of STAT3 expression with clinical outcomes
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As shown in this dissertation, BIA-ALCL tumors overexpress STAT3. More
extensive studies are needed to determine the extent of STAT3 expression in BIA-ALCL.
Specifically, future work should seek to correlate STAT3 expression across tumor stage
and determine if expression correlates with clinical outcomes, which may highlight the
role of STAT3 as a potential biomarker and prognostic indicator.
Implant surface characteristics
Perhaps the most important distinguishing feature of this disease is the marked
distinction between cases based on implant surface characteristics and, more specifically,
texturization. The lack of an association between smooth-surface breast devices and BIAALCL, as demonstrated in this dissertation, unequivocally establishes the role of
texturization in the pathogenesis of the disease. As such, concerted research efforts to
better define differences in the material properties between smooth and textured breast
devices and how potential differences can influence a host-specific response leading to
tumorigenesis are warranted.
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APPENDIX: SOUTHEASTERN SOCIETY OF PLASTIC AND RECONSTRUCTIVE
SURGEONS RESEARCH GRANT
Purpose of Project: Genetic susceptibility is thought to play a major role in the
pathogenesis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
Previous genetic studies using next-generation sequencing methods have identified
oncogenic mutations in the JAK/STAT3 pathway among several others. However, both
studies were limited by sample size and a lack of controls, making it difficult to draw
larger conclusions about the role of genetics in the pathogenesis of BIA-ALCL.
Furthermore, the manner in which these genes and others are expressed and how they
affect the tumor microenvironment in BIA-ALCL have yet to be elucidated. Thus, the
molecular mechanisms responsible for the tumorigenesis in BIA-ALCL remain
undefined, which remains a critical barrier to advancing our scientific understanding of
this disease. Gene discovery by DNA microarray has led to the identification of novel
genes in many cancers as well as major breakthroughs in tumor molecular biology. This
study aims to utilize the systematic application of transcriptome-wide microarray analysis
in banked BIA-ALCL tumor specimens and healthy control tissue in order to define the
molecular mechanisms of BIA-ALCL. Defining the molecular mechanisms of BIAALCL is essential for guiding future research efforts that ultimately seek to improve
patient safety.
Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is
an emerging and potentially lethal cancer of the immune system that is associated with
textured-surface breast implants .To date, over 500 cases have been reported worldwide,
and 16 deaths have occurred as a result of receiving this type of breast implant.
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Conversely, no cases of BIA-ALCL have been reported in patients with smooth-surface
breast implants. BIA-ALCL has been shown to occur in women undergoing breast
augmentation or post-mastectomy breast reconstruction at similar frequencies. The
number of reported cases continues to rise, with the incidence increasing 15% over the
last year alone. As such, BIA-ALCL poses a significant public health risk to women
undergoing breast augmentation or implant-based breast reconstruction. Genetic
susceptibility is thought to play a major role in the pathogenesis of this emerging cancer.
Several hypotheses attempting to explain the pathogenesis of BIA-ALCL have been
postulated. The current consensus is that BIA-ALCL occurs as a result of a chronic
inflammatory state that leads to unregulated T-cell proliferation in a genetically
susceptible individual. The exact cause of the chronic inflammation, including allergic
inflammation, remains a highly debated topic, and the molecular mechanisms by which
chronic inflammation leads to aberrant T-cell clonal expansion in BIA-ALCL have yet to
be elucidated. Arguably, only genetic predisposition in the setting of chronic
inflammation could account for the relatively low number of reported cases. Previous
genetic studies of BIA-ALCL have been limited by small sample size and a lack of
adequate controls. Previous genetic studies using next-generation sequencing methods
have identified oncogenic mutations in the JAK/STAT3 pathway among several others.
However, both studies were limited by sample size and a lack of adequate controls,
making it difficult to draw larger conclusion about the role of genetics in the pathogenesis
of BIA-ALCL. As such, the molecular mechanisms that lead to tumorigenesis in BIAALCL remain undefined which remains a critical barrier to advancing our scientific
understanding of this disease. Gene discovery by transcriptome-wide microarray has led
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to the identification of novel genes in many cancers as well as major breakthroughs in
tumor molecular biology. This study aims to utilize the systematic application of
transcriptome-wide microarray to measure differential gene expression in banked BIAALCL tumor specimens and healthy control tissue. The use of a transcriptome-wide
microarray to define the molecular mechanisms of BIA-ALCL in this study is innovative,
as is the use of a healthy control tissue for genetic comparisons. Defining the molecular
mechanisms responsible for the pathogenesis of BIA-ALCL is critical for guiding the
direction of future BIA-ALCL research and improving patient safety. For example,
uncovering differentially expressed clusters of genes tumors will assist in determining the
molecular networks that control the progression of the pathogenesis of BIA-ALCL.
Additionally, knowing how gene expression affects tumorigenesis in BIA-ALCL will
allow for the identification of oncogenic mutations in the future through targeted rather
than shotgun approaches to genetic sequencing. Lastly, derivation of such data could
have profound implications, which could ultimately lead to the development of clinical
gene arrays for pre-operative risk stratification that could identify high-risk women
undergoing breast augmentation or implant-based breast reconstruction.
Methods: This pilot study follows a case-control study design Identification, recruitment
and enrollment of eligible participants: Healthy control group (controls) Inclusion
criteria: (a) Female patients; (b) age >22 years; (c) presenting for breast implant exchange
with textured or smooth surface breast implants will be screened for study inclusion. The
control group will be identified during routine pre-operative clinic visits for breast
implant exchange at the University of Kentucky (UK), MD Anderson Cancer Center, and
the Mayo Clinic (Jacksonville). Patients will not be compensated. Drs. Vasconez,
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Clemens, Rinker, and DeCoster will be responsible for enrolling and obtaining written
informed consent from participants at their respective institutions. We expect to enroll
approximately eight participants in our control group (n=8 (smooth surface=4, textured
surface=4)). We do not anticipate problems with obtaining control samples given the
volume of implant exchange performed annually at each institution. Approximately 10mg
of breast implant capsule tissue will be collected at the time of surgery. Tissue will be
frozen and stored at -80C. The Biospecimen Procurement and Translational Pathology
Shared Resource Facility (BPTP SRF) at UK will assist with obtaining informed consent,
tissue collection, storage, and preparation of all specimens identified and received at UK.
All tissue will be de-identified. Identification, recruitment, and enrollment of eligible
participants: BIA-ALCL group (cases) FFPE/Frozen BIA-ALCL specimens (n=4) have
already been collected and are currently available at a biorepository that is directed by
Dr. Clemens and located at MD Anderson. All tissue will be de-identified. All cases have
been reviewed by a board-certified, fellowship-trained hematopathologist in order to
verify the accuracy of the BIA-ALCL diagnosis. In consultation with the Office of
Research Integrity at UK, the determination has been made that IRB approval is not
required as long as the tissue is de-identified and is for research purposes only.
RNA extraction and microarray analysis RNA will be extracted from tissues in FFPE/
frozen states using Qiagen RNeasy minikit (50) and analyzed with a 2100 Bioanalyzer
(Agilent) to ensure integrity. RNA (300 ng) from 3 independent samples per group will
be used for complementary DNA (cDNA) synthesis and labeling, using a GeneChip
Whole Transcript cDNA Synthesis and Amplification Kit and a GeneChip WT Terminal
Labeling Kit (Affymetrix). Labeled cDNA samples will be hybridized using a RES HT
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ARRAY WT Protocol on an Affymetrix HTA array plus PICO processing and will be
scanned at the Microarray Shared Resource Facility at the University of Kentucky.
Intensity scans from 3 independent GeneChips/groups will be subjected to gene
expression analysis using Partek Genomic Suite, version 7.18. Variations among the
samples in each group will be examined by principal components analysis and subjected
to hierarchical and partition clustering with the Partek Genomic Suite.
Functional gene network analysis The gene expression data derived from microarray
analysis will be subjected to Ingenuity Pathways Analysis (IPA; Ingenuity Systems) to
generate functional molecular networks. A fold change cutoff of 2.0 will be established to
identify and assign molecules to the Ingenuity Knowledge Base. Gene expression
changes will be considered in the context of physical, transcriptional, or enzymatic
interactions of the gene/gene products and then grouped according to interacting gene
networks. Expression of selected genes from cluster analysis will be confirmed by
Realtime polymerase chain reaction (PCR).
Statistical analysis Significance of differences in microarray data among cases and
controls will be analyzed with Fisher’s exact and ANOVA tests as appropriate using
Partek Genomic suite. ANOVA with Tukey’s honest significant difference post hoc test
will be applied using SPSS version 25 and will be used to determine the significance
levels of real-time PCR data. Subgroup analysis will also be performed to assess for gene
expression differences between implant surface types and to assess for temporal
differences in gene expression.
Budget:
Personnel:
143

-Henry Vasconez, MD, 1% effort $4,019
-Tim Butterfield, PhD, 1% effort $1,237
-Betsy Fink, BS, 2% effort $1,418
$314
$900
Supplies:
-Qiagen RNeasy MiniKit (50) Total RNA Isolation Kit
-Qualitative real-time PCR kit for microarray validation
-Tissue Microarray slides (12 @ $25/slide) $300
Other:
-Shipping of tumor and control specimens from collaboration sites $300
-Tissue banking of BIA-ALCL and control specimens (12 samples @ $35/sample) $420
-RNA Isolation (12 samples @ $15/sample) $180
-Test Tissue Microarray $10
-RES HT ARRAY/PICO WT PROTOCOL, Affymetrix HTA array plus Pico WT
processing
(12 specimens @ $457.39/sample) $5,489
Total: $14,587
Collaboration:
Henry Vasconez, M.D. Principal Investigator (1.0% effort) Dr. Vasconez is the William
S. Farish Endowed Chair in Plastic Surgery and is Professor of Plastic Surgery at the
University of Kentucky College of Medicine. He will assume overall responsibility for
the project. He will facilitate the accrual of study-eligible women from which control
specimens can be obtained at the University of Kentucky. Additionally, Dr. Vasconez
will be responsible for oversight of the receipt and transfer of specimens from MD
Anderson Cancer Center to the Genomics Core facility at the University of Kentucky
Markey Cancer Center. Dr. Vasconez will contribute his expertise to the analysis of data
and preparation of manuscripts related to the research.
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Tim Butterfield, Ph.D. Co-Principal Investigator (1.0% effort) Dr. Butterfield is an
Associate Professor of Rehabilitation Science and Physiology at the University of
Kentucky. He has an expertise in chronic inflammatory-related disease states and has
published several times in the area of Transcriptome-wide microarray. Dr. Butterfield
will also contribute his expertise to the analysis of data and preparation of manuscripts
related to the research.
Other Significant Contributors:
Ryan DeCoster, M.D. Dr. DeCoster is a post-doctoral research fellow within the
Division of Plastic Surgery at the University of Kentucky. Dr. DeCoster is currently
pursuing a research fellowship in plastic surgery while obtaining a Ph.D. in Clinical and
Translational Science. The focus of his dissertation is on the molecular mechanisms of
BIA-ALCL. Dr. DeCoster is currently funded under a National Institutes of Health
(NIH)/National Cancer Institute (NCI) T32 training grant. Dr. DeCoster will contribute
his expertise with data and preparation of manuscripts related to the research.
Mark Clemens, M.D. Dr. Clemens is an Associate Professor of Plastic Surgery at the
University of Texas MD Anderson Cancer Center. Dr. Clemens is considered by many as
the world’s leading expert in BIA-ALCL and has published extensively on the topic. Dr.
Clemens serves as the American Society of Plastic Surgeons (ASPS) liaison to the Food
and Drug Administration for BIA-ALCL and chairs a subcommittee for the ASPS
overseeing national research and education efforts for this cancer. He currently runs the
BIA-ALCL tissue biorepository at MD Anderson. He will facilitate the accrual of studyeligible women from which control specimens can be obtained at MD Anderson Cancer
Center. Additionally, Dr. Clemens will be responsible for overseeing the preparation and
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shipment of BIA-ALCL and control specimens from MD Anderson Cancer Center to the
University of Kentucky. Dr. Clemens will contribute his expertise with data and
preparation of manuscripts related to the research.
Brian Rinker, M.D. Dr. Rinker is Professor of Plastic Surgery at the University of
Kentucky College of Medicine. He has accepted a position as the Chief of Plastic Surgery
at the Mayo Clinic (Jacksonville). Dr. Rinker will facilitate the accrual of study-eligible
women from which control specimens can be obtained at the Mayo Clinic (Jacksonville).
Lastly, Dr. Rinker will contribute his expertise with data and preparation of manuscripts
related to the research.
Betsy Fink, BS, Research Associate (2.0% effort) Mrs. Fink has 25+ years’ experience
with clinical research study coordination on funded studies, including the National
Institutes of Health. Her role in this study will include assistance with obtaining informed
consent as well as tissue collection and serving as a liaison to the BPTP SRF and
MicroArray Core. Mrs. Fink is proficient with IRB preparation, maintenance, and
documentation for the Division of Plastic Surgery at the University of Kentucky and will
provide support to this project in those areas as well.
Facilities:
Biospecimen Procurement and Translational Pathology Shared Resource
Facility (BPTP SRF) The NCI-designated Markey Cancer Center BPTP SRF is located
on the same campus as the PI and within short walking distance. The BPTP SRF collects,
processes, annotates, stores, and distributes biospecimens to support translational
research in cancer and other diseases. BPTP SRF support includes obtaining Institutional
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Review Board (IRB) certification, collecting Informed Consents or the acquisition, and
the processing of targeted biospecimens in accordance with specific research protocols.
MicroArray Core Facility The MicroArray Core Facility at the University of Kentucky
is located a short walking distance from the office of the PI. He has access by
appointment on a fee-for-service basis. The MircoArray Core provides comprehensive
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